Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE)
Phase: PHASE4
Conditions: Idiopathic Focal Segmental Glomerulosclerosis
Sponsor: Mallinckrodt ARD LLC

&21),'(17,$/$1'35235,(7$5<
&/,1,&$/678'<35272&2/
7UHDWPHQWRI3URWHLQXULD'XHWR7UHDWPHQW5HVLVWDQWRU7UHDWPHQW
,QWROHUDQW,GLRSDWKLF)RFDO6HJPHQWDO*ORPHUXORVFOHURVLV
$3URVSHFWLYH6WXG\RI$FWKDU32'2&<7(
3URWRFRO1XPEHU01.
'DWHRI2ULJLQDO3URWRFRO 'HFHPEHU
'DWHRI3URWRFRO$PHQGPHQW$SULO
'DWHRI3URWRFRO$PHQGPHQW$XJXVW
'DWHRI3URWRFRO$PHQGPHQW2FWREHU
'DWHRI3URWRFRO$PHQGPHQW-XQH
0DOOLQFNURGW$5'//&
865RXWH
%HGPLQVWHU1-8QLWHG6WDWHVRI$PHULFD
/$5

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3 
  Page 2 of 79 
CONFIDENTIAL AND PROPRIETARY 
SUMMARY OF CHANGES 
PROTOCOL AMENDMENT 3.0 DATED 3 June 2019 
Summary of Important Changes in Amendment 3.0 
A separate Summary of Changes document is available with a comprehensive list of changes 
from Amendment 2.1 to Amendment 3.0. 

The title page was updated to reflect the regulatory requirement to use the
Mallinckrodt ARD LLC corporate headquarters address in Bedminster, New Jersey.

Changed enrolled population from 236 to 60 subjects.

Removed the double-blind, placebo-controlled randomization maintenance period
(week 26, including removing the forced taper starting at Week 26, to Week 50) to
extend the open label/open-label extension period (Week 26 to Week 50).

Changed primary objective from confirmation of efficacy to confirmation of safety
and tolerability.

Changed primary endpoints to
 Severity and frequency of AEs
 Changes in physical findings
 Changes in clinical laboratory findings
 Changes in vital signs

Removed all secondary objectives and endpoints.

Removed all exploratory objectives in Amendment 2.1. Replaced with 

Removed all exploratory endpoints from Amendment 2.1. Replaced with
 
 
 
 
 
 
 
 
 
 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 3 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 
  
 
 
 
 
 
 
 
 
 Descriptive statistics only.  
 Reformatted to new Mallinckrodt format. Section numbering, table and figure 
numbering, and internal section references were adjusted in the amended protocol 
 
PROTOCOL AMENDMENT 2.1 DATED 12 OCTOBER 2017 
Summary of Changes in Amendment 2.1 
 
The following changes from protocol Amendment 2 to Amendment 2.1 where made: 
1. The title page was updated to reflect the regulatory requirement to use the Mallinckrodt 
ARD, Inc. corporate headquarters address in Hazelwood, Missouri. 
2. Section 2 (Contacts) was deleted. This information will be supplied in the Study 
Operations Manual with updates to that document as needed. The Emergency Contacts 
list in the Study Operations Manual will be revised to remove 
 
 as medical monitors. 
 will remain as regional 
medical monitors. Section numbering and internal section references were adjusted in the 
amended protocol based on this deletion. 
3. International Council on Harmonisation was changed to International Council for 
Harmonisation globally.  
4.  Week 24 is noted as Visit 8 throughout the protocol. 
5. Corresponding appropriate changes were made to the study synopsis (Section 1.1). 
6. The abbreviation 
 was added to abbreviation list. 
 was used 
throughout the protocol. 
7. Serum sampling for cortisol determination was removed as an safety assessment from 
Table 1 (Schedule of Study Events, Section 1.4), Section 8 (Procedures), Section 10 
(Safety Assessments and Procedures), Section 10.7 (Clinical Laboratory Tests, HbA1c, 
, IGRA, Urinalysis, and Pregnancy Tests), and 
Section 24.1 (Attachment 1: Clinical Laboratory Tests). It was recognized that there is no 
endpoint associated with the assessment and 
 
 
. 
8. 
on was added to screening at Visit 1. Table 1 (Schedule of Study 
Events, Section 1.4) was revised to add a separate row for 
with a determination 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 4 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
indicated at Visit 1. Section 8 (Procedures) was revised to include the 
 
determination to the Visit 1. 
9. The timing of the Baseline Visit/Visit 2 was revised if the subject had no treatment at 
Screening Visit/Visit 1 to “Eligibility is confirmed and IMP is on-site” in Table 1 
(Section 8.2).  
10. Willingness to undergo 
 
, was added to Inclusion Criterion 5 (Section 6.1). Table 1 (Schedule of Study 
Events, Section 1.4) and Section 6.1 (Inclusion Criteria) were revised to reflect this new 
criterion. Section 13 (Procedures) was revised to include the 
 at Visit 1. 
11. Male contraception was removed from Inclusion Criterion 4 (Section 6.1). There is no 
relevant data to indicate a teratogenic, or genotoxic risk of ACTH peptides in Acthar. 
12. The qualifying urine protein creatinine ratio in Inclusion Criterion 6 (Section 6.1) was 
changed from greater than 3.5 mg/mg to greater than 3.0 mg/mg.  
13. Cyclophosphamide was added to medications prohibited 24 weeks before screening at 
Visit 1 Exclusion Criterion 24 (Column 1, Table 2) was revised to add 
"cyclophosphamide" to the column. Cyclophosphamide was added to prohibited 
medications because of its long pharmacodynamic half-life. The title to Table 2 was 
inadvertently changed from “Screening Visit/Visit 1” to “Screening Visit/Visit.” 
14. The title to Table 2 was corrected from “Screening Visit/Visit” to “Screening Visit/Visit 
1.” 
15. Mathematical operators were removed globally for better readability. Inadvertent errors 
in Exclusion Criterion 27 (Section 6.2) were made in the conversion of mathematical 
symbols to text in Protocol Amendment 2.0; these have been corrected.  
16. The definition of screen failures was revised to allow only one repeat measurement 
(Section 6.3 and Section 8.1). The following text was added to Section 8.1: “A screening 
procedure can be repeated only once; if the repeat procedure continues to be 
exclusionary, the subject will be a screen failure.” 
17. Prohibited concomitant medications (Section 7.1) were revised to include any long-acting 
corticotropin, other than Acthar, and to allow intraocular immunosuppressive 
medications. 
18. Expanded the information to be conveyed during the IXRS contact (Section 9.1). 
Replaced the text “The investigator or designee must contact the IXRS to update the 
subject’s status” with the text “
 
 during the 
IXRS contact; appropriate kit assignment will be made following this determination.” 
19. Time durations in Table 5 (Section 9.3, Dosing Procedures) were revised in Column 1. 
Footnotes b and c to Table 5 were changed from Week 23 to Week 24. 
20. Dosing procedures (Section 9.3) were updated to include information regarding 
restrictions on dosing. The text “Throughout the trial, IMP cannot be taken on 2 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 5 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
consecutive days and cannot be taken more than 3 days apart, regardless of dosing 
frequency,” was added. 
21. The text “The investigator or designee must contact the IXRS to update the subject’s 
status” was removed from Section 9.1 (Methods of Assigning Subjects to Treatment 
Groups). 
22. Added the following text reporting and recording of AEs to Section 10.1, “AEs occurring 
prior to the administration of IMP will only be reported if they are related to study 
procedures.” 
23. The text “…Screening Visit/Visit and…” was changed to “…Screening Visit/Visit 1 
and…” in Section 10.5. 
24. Definitions relating to 
 
 
 
 
was added. 
25. The exploratory endpoints 
 
 
26. Refined the definition of visits to the emergency department in Section 13.2 so that they 
are not considered SAEs in Mallinckrodt clinical studies. 
27. Clarified the collection times for AEs and SAEs will begin from the time of signing of 
the informed consent form through the end-of-study/early termination visit in Section 
13.4. Also added the text, “All AEs and SAEs should be recorded in source documents; 
all AEs and SAEs that occur following the first dose of IMP should also be recorded in 
the eCRF.” 
28. Carbon dioxide and sodium were inadvertently removed from the listing of clinical 
laboratory tests in Attachment 1 (Section 24.1). These analytes will be collected. 
29. Additional unspecified minor changes to punctuation, style, and formatting. 
 
 
PROTOCOL AMENDMENT 2 DATED 22 AUGUST 2017 
SUMMARY OF CHANGES 
 
Protocol Amendment 2 was developed primarily to add 
as a screening procedure. 
Additional revisions were made to clarify other specific protocol issues. The protocol changes 
are summarized below: 
1. Section 2 (Contacts) was deleted. Remaining sections located after Section 1 were 
renumbered. 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 6 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
2. Section 1.4 (Schedule of Study Events) and Section 6.1 (Inclusion Criteria) were revised 
to add 
as a screening procedure unless performed in the prior 3 years (new 
inclusion criterion #5). 
3. Section 6.2 (Table 2) was revised to add a separate row for 
 with an extra ‘X’ at the 
Screening Visit. 
4. Section 6.1 (Inclusion Criteria) Inclusion criterion #4 was revised to remove the 
requirement for male contraception. Inclusion criterion #6 was revised to change 
 
 
5. Section 6.1 (Inclusion Criteria - inclusion criterion #9) and Section 7.2 (Permitted During 
Study) were revised to delete “DRI” since DRI drugs have not been shown to improve 
renal function. 
6. Section 6.2 (Exclusion Criteria) - Exclusion criterion #9 was revised to change 
“senescence” to “sclerosis”. Exclusion criterion #24 (Table 11-1, column 1) was revised 
to add "cyclophosphamide" to the 24 weeks before Screening Visit/Visit 1 column, since 
cyclophosphamide is used as a treatment for FSGS and has a very long 
pharmacodynamic half-life. Exclusion criterion #27 was revised for better readability. 
7. Section 12.3.1 (Primary Efficacy Endpoint). Table 6 was revised, 
 
 
8. Section 13.4 was revised to clarify the reporting and recording of AEs. 
9. Corresponding appropriate changes were also made to Section 1.1 (Study Synopsis). 
10. Global edits were made to revise the number of study sites from 80 to 100 and the study 
duration from 4 years to 5 years. 
11. Formatting changes were made globally as necessary for medical writing style guide 
compliance. 
 
 
 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 7 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
PROTOCOL AMENDMENT 1 DATED 20 APRIL 2016 
SUMMARY OF CHANGES 
 
Protocol Amendment 1 was developed primarily to modify eligibility criteria. Additional 
revisions were made to adjust other procedures and descriptions. The major protocol changes are 
summarized below: 
 Deleted “(US and Canada only)” as the location of where 
 would 
be conducted. 
 Revised the Emergency Contacts list to remove 
 as a backup medical 
monitor, and to add 
 as 
medical monitors. 
 Revised Inclusion Criterion #5 to allow time from 
 
 
 Added Exclusion Criterion #8: Subjects cannot have failed to achieve 
 
, as determined by the investigator, on more than 2 prior 
immunosuppressive therapies with different mechanisms of action. 
 The following Secondary Endpoints were deleted or revised: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 8 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The following Exploratory Endpoints were deleted or revised:  
 
 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 9 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 10 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 11 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The following Secondary Efficacy Endpoints were added/revised: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 12 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 
 
 
 
 The following Secondary Safety Endpoint was added:  
 Summary of general safety profile, including adverse events (serious and non-
serious), vital signs, and laboratory assessments by study period and over the 
entire study. 
 The following Exploratory Endpoints were added/revised: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 13 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 
 
 
 
 
 
 
  

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 14 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
TABLE OF CONTENTS 
CLINICAL STUDY PROTOCOL ..................................................................................................1 
TABLE OF CONTENTS ...............................................................................................................14 
LIST OF TABLES .........................................................................................................................19 
LIST OF FIGURES .......................................................................................................................19 
DISCLOSURE STATEMENT ......................................................................................................20 
SPONSOR SIGNATURE ..............................................................................................................21 
INVESTIGATOR SIGNATURE...................................................................................................22 
ABBREVIATIONS .......................................................................................................................23 
1. 
PROTOCOL SUMMARY ..........................................................................................26 
1.1. 
SYNOPSIS .................................................................................................................26 
1.2. 
STUDY SCHEMATIC AND SCHEDULE OF EVENTS .........................................29 
1.3. 
Study Schematic .........................................................................................................29 
1.4. 
Schedule of Study Events ...........................................................................................30 
2. 
ETHICAL CONSIDERATIONS................................................................................33 
2.1. 
Institutional Review Board/Independent Ethics Committee ......................................33 
2.2. 
Ethical Conduct of the Study ......................................................................................33 
2.3. 
Subject Information and Consent ...............................................................................33 
3. 
BACKGROUND INFORMATION AND RATIONALE..........................................34 
3.1. 
Overview .....................................................................................................................34 
3.2. 
Product Description ....................................................................................................36 
3.3. 
Dosage and Administration ........................................................................................36 
3.4. 
Rationale .....................................................................................................................36 
3.5. 
Risk/Benefit ................................................................................................................37 
4. 
OBJECTIVES .............................................................................................................37 
4.1. 
Primary Objective .......................................................................................................37 
4.2. 
Secondary Objectives .................................................................................................38 
4.3. 
Exploratory Objective(s) ............................................................................................38 
5. 
STUDY DESIGN .......................................................................................................39 
5.1. 
Description ..................................................................................................................39 
5.2. 
Approximate Duration of Subject Participation .........................................................39 
5.3. 
Approximate Duration of Study .................................................................................39 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 15 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
5.4. 
Approximate Number of Subjects ..............................................................................39 
6. 
SELECTION OF SUBJECTS ....................................................................................39 
6.1. 
Inclusion Criteria ........................................................................................................39 
6.2. 
Exclusion Criteria .......................................................................................................40 
6.3. 
Screen Failure .............................................................................................................43 
7. 
PRIOR AND CONCOMITANT MEDICATION ......................................................44 
7.1. 
Prohibited Concomitant Medications .........................................................................44 
7.2. 
Permitted During Study ..............................................................................................44 
8. 
PROCEDURES ..........................................................................................................44 
8.1. 
Screening Visit/Visit 1 (Study Days -63 to -3) Procedures ........................................44 
8.2. 
Baseline Visit/Visit 2 Procedures ...............................................................................46 
8.3. 
Visit 3 Procedures (Week 4 ± 5 Days) .......................................................................46 
8.4. 
Visit 4 Procedures (Week 8 ± 5 Days) .......................................................................47 
8.5. 
Visit 5 Procedures (Week 12 ± 5 Days) .....................................................................47 
8.6. 
Visit 6 Procedures (Week 16 ± 5 Days) .....................................................................48 
8.7. 
Visit 7 Procedures (Week 20 ± 5 Days) .....................................................................48 
8.8. 
Visit 8 Procedures (Week 24 ± 5 Days) .....................................................................49 
8.9. 
Visit 9 Procedures (Week 26 + 5 Days) .....................................................................49 
8.10. 
Visit 10 Procedures (Week 30 ± 5 Days) ...................................................................50 
8.11. 
Visit 11 Procedures (Week 34 ± 5 Days) ...................................................................50 
8.12. 
Visit 12 Procedures (Week 38 ± 5 Days) ...................................................................51 
8.13. 
Visit 13 Procedures (Week 42 ± 5 Days) ...................................................................51 
8.14. 
Visit 14 Procedures (Week 46 ± 5 Days) ...................................................................52 
8.15. 
Visit 15 Procedures (Week 50 ± 5 Days) ...................................................................52 
8.16. 
End of Study/Early Termination Visit Procedures .....................................................53 
8.17. 
Taper Safety Visit .......................................................................................................53 
9. 
INVESTIGATIONAL MEDICINAL PRODUCT .....................................................54 
9.1. 
Methods of Assigning Subjects to Treatment Groups ................................................54 
9.2. 
Emergency Identification of Investigational Medicinal Product ................................54 
9.3. 
Dosing Procedures ......................................................................................................54 
9.3.1. 
Dose Reduction ...........................................................................................................55 
9.3.2. 
Treatment Discontinuation .........................................................................................55 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 16 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
9.4. 
Description of IMP .....................................................................................................56 
9.5. 
Storage of Clinical Supplies .......................................................................................57 
9.6. 
Drug Accountability ...................................................................................................57 
9.7. 
Compliance Monitoring ..............................................................................................57 
10. 
SAFETY ASSESSMENTS AND PROCEDURES ....................................................57 
10.1. 
Adverse Events ...........................................................................................................57 
10.2. 
Medical and Surgical History .....................................................................................58 
10.3. 
Current Medical Conditions .......................................................................................58 
10.4. 
Physical Examinations ................................................................................................58 
10.5. 
Vital Signs ..................................................................................................................58 
10.6. 
Height and Weight ......................................................................................................59 
10.7. 
Clinical Laboratory Tests, HbA1c, 
 
IGRA, Urinalysis, and Pregnancy Tests .................................................59 
11. 
EXPLORATORY ASSESSMENTS ..........................................................................60 
11.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
12. 
STATISTICAL METHODS AND PLANNED ANALYSIS .....................................61 
12.1. 
General Considerations ...............................................................................................61 
12.2. 
Analysis Populations ..................................................................................................62 
12.3. 
Efficacy Assessments .................................................................................................62 
12.3.1. 
Primary Efficacy Endpoint .........................................................................................62 
12.3.2. 
Secondary Efficacy Endpoints ....................................................................................62 
12.4. 
Primary Safety Endpoints ...........................................................................................62 
12.5. 
Exploratory Endpoints ................................................................................................62 
12.6. 
Subject Characteristics ................................................................................................63 
12.6.1. 
Demographics .............................................................................................................63 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 17 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
12.6.2. 
Medical and Surgical History .....................................................................................63 
12.6.3. 
Concomitant Medications ...........................................................................................63 
12.6.4. 
Subject Disposition and Exposure to IMP ..................................................................64 
12.7. 
Safety Analysis ...........................................................................................................64 
12.7.1. 
Adverse Events ...........................................................................................................64 
12.7.2. 
Clinical Laboratory Tests ...........................................................................................64 
12.7.3. 
Physical Examination Findings ..................................................................................64 
12.7.4. 
Vital Signs/Height and Weight ...................................................................................64 
12.8. 
Interim Analysis ..........................................................................................................64 
12.9. 
Statistical Power and Sample Size Consideration ......................................................64 
12.10. 
Deviations From Statistical Analysis Plan .................................................................64 
13. 
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS ..................................65 
13.1. 
Safety ..........................................................................................................................65 
13.2. 
Definitions ..................................................................................................................65 
13.3. 
Adverse Event and Serious Adverse Event Classifications ........................................66 
13.4. 
Adverse Event and Serious Adverse Event Recording and Reporting .......................67 
13.5. 
Pregnancy Reporting ..................................................................................................69 
14. 
SUBJECT DISCONTINUATION OR WITHDRAWAL ..........................................70 
14.1. 
Subject Withdrawal ....................................................................................................70 
15. 
STUDY SUSPENSION, TERMINATION, AND COMPLETION ...........................71 
16. 
PROTOCOL AMENDMENTS ..................................................................................71 
17. 
QUALITY CONTROL AND ASSURANCE ............................................................71 
17.1. 
Study and Study Site Discontinuation Criteria ...........................................................72 
18. 
DIRECT ACCESS, DATA HANDLING, AND RECORD-KEEPING ....................72 
18.1. 
Investigator .................................................................................................................72 
18.2. 
Sponsor .......................................................................................................................72 
19. 
SUBJECT INJURY ....................................................................................................73 
20. 
RECORDS RETENTION ..........................................................................................73 
21. 
BIOLOGICAL SAMPLES .........................................................................................73 
22. 
PUBLICATION POLICY ..........................................................................................73 
22.1. 
Sponsor’s Publication Policy ......................................................................................73 
22.2. 
Investigator’s Ability to Publish .................................................................................74 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 18 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
23. 
REFERENCES ...........................................................................................................74 
24. 
ATTACHMENTS .......................................................................................................76 
24.1. 
Attachment 1: Clinical Laboratory Tests ....................................................................76 
24.2. 
Attachment 2: Evaluation of Edema ...........................................................................77 
24.3. 
Attachment 3: Secondary Causes of FSGS ................................................................78 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 19 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
LIST OF TABLES 
Table 1: 
Schedule of Study Events ...........................................................................................30 
Table 2: 
Prohibited Medications Relative to Screening Visit/Visit 1 .......................................42 
Table 3: 
Prohibited Medications Relative to Baseline Visit/Visit 2 .........................................42 
Table 4: 
Timing of Baseline Visit/Visit 2 Relative to FSGS Treatment at Screening .............45 
Table 5: 
IMP Treatment Schedule ............................................................................................55 
Table 6: 
62 
Table 7: 
Adverse Event Relationships ......................................................................................66 
Table 8: 
Adverse Event Severity Grades ..................................................................................67 
Table 9: 
Reporting Requirements for Adverse Events .............................................................68 
 
LIST OF FIGURES 
Figure 1: 
Study Overview ..........................................................................................................29 
  
 
 
 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 20 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
DISCLOSURE STATEMENT 
Restricted Distribution of Documents 
This document contains information that is confidential and proprietary to the sponsor. This 
information is being provided to the investigator solely for the purpose of evaluating and/or 
conducting a clinical study for the sponsor. The investigator may disclose the contents of this 
document only to study personnel under his/her supervision, institutional review boards 
(IRBs)/independent ethics committees (IECs), or duly authorized representatives of regulatory 
agencies for this purpose under the condition that they maintain confidentiality. The contents of 
this document may not be used in any other clinical study, disclosed to any other person or 
entity, or published without the prior written permission of the sponsor. The foregoing shall not 
apply to disclosure required by any regulations; however, the investigator will give prompt 
notice to the sponsor of any such disclosure. All other nonpublic information provided by the 
sponsor, as well as any information that may be added to this document, also is confidential and 
proprietary to the sponsor and must be kept in confidence in the same manner as the contents of 
this document. 
 
 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 21 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
SPONSOR SIGNATURE 
My signature, in conjunction with the signature of the investigator, confirms the agreement of 
both parties that the clinical study will be conducted in accordance with the protocol and 
applicable laws and other regulations including, but not limited to, the International Council for  
Harmonisation (ICH) Guideline for Good Clinical Practice (GCP), the US Code of Federal 
Regulations (CFR) (where applicable), all applicable national and local regulations, protections 
for privacy, and generally accepted ethical principles for human research such as the Declaration 
of Helsinki. 
Nothing in this document is intended to limit the authority of a physician to provide emergency 
medical care. 
 
 
Sponsor Signature 
 
Date of Signature 
(DD Month YYYY) 
 
 
 
 
Sponsor Name (print) 
 
 
 
 
@mallinckrodt.com
Digitally signed by 
@mallinckrodt.com 
DN: cn
@mallinckrodt.com 
Reason: I am approving this document 
Date: 2019.06.03 16:44:32 -04'00'

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 22 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
INVESTIGATOR SIGNATURE  
My signature confirms that the clinical study will be conducted in accordance with the protocol 
and applicable laws and other regulations including, but not limited to, the International Council 
for Harmonisation (ICH) Guideline for Good Clinical Practice (GCP), the US Code of Federal 
Regulations (CFR) (where appropriate), all applicable national and local regulations, protections 
for privacy, and generally accepted ethical principles such as the Declaration of Helsinki. 
Nothing in this document is intended to limit the authority of a physician to provide emergency 
medical care. 
 
 
 
Investigator’s Signature 
 
Date of Signature 
(DD Month YYYY) 
 
 
 
 
Investigator’s Name and Title (print) 
 
 
 
 
 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 23 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
ABBREVIATIONS 
Abbreviation 
Term 
2x/week 
Twice a week 
3x/week 
Three times a week 
ACEi 
Angiotensin-converting enzyme inhibitor 
ACTH 
Adrenocorticotropic hormone 
AE 
Adverse event 
ALT 
Alanine aminotransferase 
ANC 
Absolute neutrophil count 
ARB 
Angiotensin receptor blocker 
AST 
Aspartate aminotransferase 
BMI 
Body mass index 
CFR 
Code of Federal Regulations 
CNI 
Calcineurin inhibitor 
CR 
Complete remission 
eCRF 
Electronic case report form 
eGFR 
Estimated glomerular filtration rate 
ESRD 
End stage renal disease 
FDA 
Food and Drug Administration 
FSGS 
Focal segmental glomerulosclerosis 
GCP 
Good Clinical Practices 
HbA1c 
Glycosylated hemoglobin 
HBsAg 
Hepatitis B surface antigen 
HBcAb 
Hepatitis B core antibody 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 24 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
Abbreviation 
Term 
HCV 
Hepatitis C virus antibody 
HCV PCR 
Hepatitis C virus polymerase chain reaction 
HIPAA 
Health Insurance Portability and Accountability Act 
HIV 
Human immunodeficiency virus 
ICF 
Informed consent form 
ICH 
International Council for Harmonisation 
ID 
Identification 
IEC 
Independent Ethics Committee 
IGRA 
Interferon gamma release assay 
IMP 
Investigational medicinal product 
IRB 
Institutional Review Board 
ITT 
Intent-to-treat 
IXRS 
Interactive Phone/Web Response System 
KDIGO 
Kidney Disease Improving Global Outcomes 
LDL 
Low density lipoprotein 
MCR 
Melanocortin receptor 
MDRD 
Modification of Diet in Renal Disease 
MMF 
Mycophenolate mofetil 
PR 
Partial remission 
SAE 
Serious adverse event 
SC 
Subcutaneous 
SF-36 
Short Form (36) Health Survey  
TB 
Tuberculosis 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 25 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
Abbreviation 
Term 
TEAE 
Treatment-emergent adverse event 
U 
Unit(s) 
US 
United States 
ULN 
Upper limit of normal 
uPCR 
Urine protein creatinine ratio 
 
 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 26 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
1. 
PROTOCOL SUMMARY 
1.1. 
SYNOPSIS  
Study Title: Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic 
Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE) 
Protocol Number: MNK14224049 
Type: Phase 4 (US)/Phase 2 (all other countries) 
Condition/Disease: Idiopathic focal segmental glomerulosclerosis (FSGS) 
Approximate Number of Subjects: 60 
Approximate Duration of Subject Participation: Up to 65 weeks 
Approximate Number of Study 
Centers: 100 globally 
Approximate Duration of Study: 5 years 
Design: 
This is a multicenter, multiple dose study to examine the effect of Acthar (repository corticotropin injection, 
hereafter referred to as Acthar) in adult subjects with idiopathic focal segmental glomerulosclerosis (FSGS) who 
have failed to achieve remission with, or who are intolerant of, 1 or more previous immunosuppressive therapies. 
All enrolled subjects will be treated in an unblinded fashion with Acthar 1 mL (80 U) subcutaneously (SC) 
3 times per week (3x/week) for 50 weeks to assess the safety and tolerability of Acthar. Taper to 1 mL SC twice a 
week (2x/week) for tolerability reasons will be allowed. All subjects will have an End of Study/Early 
Termination Visit 4 weeks after discontinuing Investigational Medicinal Product (IMP). 
Objectives and Endpoints:  
Primary Objective 
Primary Endpoints 
To confirm the safety and tolerability of 
Acthar in the induction of remission of 
proteinuria in subjects with primary FSGS 
who are resistant to, or intolerant of, at 
least 1 prior immunosuppressive therapy 
 
Severity and frequency of adverse events (AEs) 
 
Changes in physical findings 
 
Changes in clinical laboratory findings 
 
Changes in vital signs 
 
Secondary Objective 
Secondary Endpoint 
None 
None 
Exploratory Objective 
Exploratory Endpoints 
 
To demonstrate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 27 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
Study Title: Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic 
Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE) 
Protocol Number: MNK14224049 
Type: Phase 4 (US)/Phase 2 (all other countries) 
Condition/Disease: Idiopathic focal segmental glomerulosclerosis (FSGS) 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Entry Criteria: 
Male or nonpregnant, nonlactating female subjects 18 years of age or older with primary FSGS (confirmed by 
renal biopsy) who are nephrotic (uPCR  3.0 mg/mg and estimated glomerular filtration rate [eGFR] at 
least 30 mL/min/1.73 m2) and who have failed to achieve sustained CR or PR of proteinuria with at least 1 prior 
immunosuppressive therapy OR intolerance at least 1 prior immunosuppressive therapy will be enrolled in the 
study. Subjects must be treated with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker 
(or have documentation of intolerance), for at least 4 weeks prior to Screening Visit/Visit 1 with blood pressure 
no more than 150/90. Subjects also must be negative for hepatitis B, hepatitis C, have no history of tuberculosis 
(TB) or other contraindication as per the United States (US) Prescribing Information for Acthar, have no history 
of Type 1 or Type 2 diabetes mellitus, or have any clinically significant infection. Subjects cannot have taken 
Rituximab or cyclophosphamide 24 weeks prior to Screening Visit/Visit 1, any investigational treatments for 
FSGS or oral corticosteroids (unless used to treat FSGS) for 12 weeks prior to Screening Visit/Visit 1, any 
intravenous/intramuscular corticosteroids (unless used to treat FSGS) for 8 weeks prior to Screening Visit/Visit 1, 
or have been involved in a therapeutic drug/device trial (other than for FSGS) 4 weeks prior to Screening 
Visit/Visit 1. 
Concomitant Medications and Treatments: 
A stable dose of angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker is required throughout 
study participation. Subjects requiring other antihypertensive medications must be on a stable dose at least 4 
weeks prior to the first dose of Acthar. 
Subjects are not permitted to take any enteral or parenteral corticosteroid, live or live-attenuated vaccine or 
systemic immunosuppressive medication during the study. 
All medications and nondrug therapies (eg, blood transfusions, oxygen supplementation) at Screening Visit/Visit 
1 and throughout the study will be recorded. 

Mallinckrodt ARD LLC 
MNK1422  
Protocol MNK14224049 Amendment 3                                                                             Page 28 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
Study Title: Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic 
Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE) 
Protocol Number: MNK14224049 
Type: Phase 4 (US)/Phase 2 (all other countries) 
Condition/Disease: Idiopathic focal segmental glomerulosclerosis (FSGS) 
Investigational Medicinal Product and Treatment Administration: 
Acthar 1 mL (80 U) SC 3x/week will be administered to all subjects from Week 0 to 50. Tapering of dose to 
1 mL SC 2x/week will be allowed for safety and/ tolerability issues. Once the dose is tapered to 1 mL SC 
2x/week it must remain at this level. Subjects unable to tolerate 1 mL SC 2x/week will be discontinued. 
Efficacy Evaluations: 
There are no efficacy assessments. 
Safety Evaluations:  
The following safety assessments will be evaluated: adverse events, physical examinations, clinical laboratory 
tests, vital signs, medical and surgical history, height and height.  
Exploratory Evaluations: 
The following exploratory assessments will be evaluated: 
 
 
 
Statistical Methods: 
Analysis Populations: 
Intent-to-Treat (ITT) Population: All enrolled subjects who receive 1 or more doses of IMP and who contribute 
any exploratory data to the study. 
Per-Protocol Population: the subset of the ITT population who complete the study as per protocol. Completer 
populations will be further defined in the statistical analysis plan. 
Safety Population: all enrolled subjects who receive 1 or more doses of IMP. 
Sample Size: 
Approximately 60 subjects will be enrolled. Formal sample size calculations were not performed.  
Assessments: 
Efficacy: There are no efficacy endpoints. 
Safety: The following safety assessments will be evaluated: adverse events, physical examinations, clinical 
laboratory tests, vital signs, medical and surgical history, height and height.  
Exploratory: Exploratory endpoints will be summaries with descriptive statistics only. 
 
 
 
 
 

Mallinckrodt ARD LLC 
MNK1422 
Protocol 14224049 Amendment 3 
                                                                                                                                                        Page 29 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
1.2. 
STUDY SCHEMATIC AND SCHEDULE OF EVENTS 
1.3. 
Study Schematic 
Figure 1: 
Study Overview 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screening 
Open Label/Open-label Extension  Acthar 1 mL (80 U) 
SC 3x/w 
Follow-up Period 
Day -63 – Day -3 
 
Weeks 53-56 
Taper to Acthar 1 mL (80U) SC 2x/w 
permitted for safety 
Weeks 51 – 54  
Weeks 0 – 50  
Weeks 51 – 52  
Taper  
to 2x/w 
Follow-up 
Period 

Mallinckrodt ARD LLC 
MNK1422 
Protocol 14224049 Amendment 3 
                                                                                                                                                        Page 30 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
1.4. 
Schedule of Study Events 
Table 1: 
Schedule of Study Events 
Period 
Screening 
(Day -63 
to -3) 
Baseline 
Open Label/Open-label Extension  
 
Taper Safety Visita 
End of Study/Early 
Terminationb 
VISIT #: Visit window is ± 5 days 
starting with Visit 2 (except at 
V9 where window is + 5 days 
only) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Week 
 
0 
4 
8 
12 
16 
20 
24 
26 
30 
34 
38 
42 
46 
50 
 
54 or 
56 
Informed consentc 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/exclusion criteria review 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical/surgical history 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current medical condition review 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Complete physical examination 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Limited physical examination 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Vital signs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Height (screening only) and weight 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Clinical laboratory tests (serum 
chemistry and CBC w/diff) 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
X 
X 
X 
X 
X 
Xd 
X 
HbA1c 
X 
 
 
 
X 
 
 
X 
 
 
 
X 
 
 
X 
 
 
Nonfasting lipid panel 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
 
X 
 
 
 
 
X 
 
X 
 
X 
 
X 
 
 
X 
 
X 
 
X 
 
 
 
X 
X 
 
X 
 
X 
 
X 
 
 
X 
 
X 
 
X 
 
 

Mallinckrodt ARD LLC 
MNK1422 
Protocol 14224049 Amendment 3 
                                                                                                                                                        Page 31 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
Period 
Screening 
(Day -63 
to -3) 
Baseline 
Open Label/Open-label Extension  
 
Taper Safety Visita 
End of Study/Early 
Terminationb 
VISIT #: Visit window is ± 5 days 
starting with Visit 2 (except at 
V9 where window is + 5 days 
only) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Week 
 
0 
4 
8 
12 
16 
20 
24 
26 
30 
34 
38 
42 
46 
50 
 
54 or 
56 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
X 
 
X 
 
 
X 
 
X 
 
X 
 
 
Serum pregnancy test 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IGRA for TB 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
 
X 
 
X 
 
X 
 
 
X 
 
X 
 
X 
 
X 
Urine pregnancy test 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
s 
X 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IXRS contact 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
IMP and diary training 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
 
Xf 
 
 
IMP accountability 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Xf  
Dispense IMP kits 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Xf  
 
 
Administer first doseg 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diary review 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 

Mallinckrodt ARD LLC 
MNK1422 
Protocol 14224049 Amendment 3 
                                                                                                                                                        Page 32 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
Period 
Screening 
(Day -63 
to -3) 
Baseline 
Open Label/Open-label Extension  
 
Taper Safety Visita 
End of Study/Early 
Terminationb 
VISIT #: Visit window is ± 5 days 
starting with Visit 2 (except at 
V9 where window is + 5 days 
only) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Week 
 
0 
4 
8 
12 
16 
20 
24 
26 
30 
34 
38 
42 
46 
50 
 
54 or 
56 
 
 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
Concomitant medications/adverse 
events 
-----------------------------------------------------------X------------------------------------------------------------------------- 
aIf IMP is tapered from 3x/week to 2x/week for safety and/or tolerability issues, a Taper Safety Visit will be conducted 2 weeks later (See Section 8.17).  
bSubjects receiving 2x/week dosing (tapered for safety) will return at Week 54 + 5 days and subjects dosing 3x/week will return at Week 56 + 5 days. 
cSubjects (US only) with stored 
 will be reconsented after implementation of Amendment 3 to allow for sponsor/site contact and permission for additional sample 
examination. 
dClinical laboratory tests will be done if the reason for discontinuation was related to laboratory test results. 
eR
 
 
fFor subjects requiring IMP taper only. 
gSubject or subject’s caregiver will administer the first dose of IMP in the clinic under the supervision of the study staff. The subject will be observed in the clinic for at least 1 hour postdose 
to monitor for allergic or anaphylactic reactions. 
 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 33 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
2. 
ETHICAL CONSIDERATIONS 
This clinical study is designed to comply with ICH Guidance on General Considerations for 
Clinical Trials and applicable national and local regulations. 
2.1. 
Institutional Review Board/Independent Ethics Committee 
It is the responsibility of the investigator to obtain the approval of the IRB/ IEC before the start 
of the study. The investigator will provide Mallinckrodt with a statement of compliance from the 
IRB/IEC and/or the US Department of Health and Human Services general assurance number. A 
copy of the approval letter along with a roster of IRB/IEC members and compliance letter and/or 
the US Department of Health and Human Services general assurance number will be retained as 
part of the study records. During the course of the study, the investigator will provide timely and 
accurate reports to the IRB/IEC on the progress of the study at appropriate intervals (not to 
exceed 1 year) and at the completion of the study. The investigator will notify the IRB/IEC of 
SAEs or other significant safety findings per IRB/IEC guidelines. The study protocol, informed 
consent form (ICF), advertisements (if any), and amendments (if any) will be approved by the 
IRB/IEC in conformance with international, national and local regulatory requirements; and the 
Code of Federal Regulations (CFR), Title 21, Part 56 (where applicable). 
2.2. 
Ethical Conduct of the Study 
The study will be conducted in full compliance with applicable international, national and local 
regulatory requirements; United States (US) Food and Drug Administration (FDA) regulations 
including 21 CFR 314.106 and 312.120, (where applicable); and ICH guidelines for GCP and in 
accordance with the ethical principles that have their origins in the Declaration of Helsinki. 
2.3. 
Subject Information and Consent 
The ICF must be approved by the sponsor and the IRB/IEC before any subject provides consent. 
The investigator will provide Mallinckrodt with a copy of the IRB/IEC-approved ICF and a copy 
of the IRB/IEC’s written approval before the start of the study. 
At the Screening Visit/Visit 1, subjects will read the ICF and a Health Insurance Portability and 
Accountability Act (HIPAA) authorization form (if applicable) after being given an explanation 
of the study. Before signing the ICF and the HIPAA authorization form (if applicable), subjects 
will have an opportunity to discuss the contents of these forms with study site personnel.  
Subjects must assent understanding of and voluntarily sign these forms in compliance with ICH 
GCP guidelines and 21 CFR, Parts 50 and 312 (where applicable), before participating in any 
study-related procedures. Subjects will be made aware that they may withdraw from the study at 
any time. Subjects unable to give written informed consent must orally assent to the procedures, 
and written informed consent must be obtained from a legally authorized representative in 
accordance with national and local laws, as applicable. 
The ICF must contain all applicable elements of informed consent and the mandatory statements 
as defined in by national and local regulations including confidentiality. All versions of each 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 34 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
subject's signed ICF must be kept on file by the site for possible inspection by regulatory 
authorities and/or authorized Mallinckrodt personnel. Signed copies of the ICF and the HIPAA 
authorization form, if applicable, will be given to the subject.  
The subjects will be made aware of their right to see and copy their records related to the study 
for as long as the investigator has possession of this information. If the subject withdraws 
consent and/or HIPAA authorization, the investigator can no longer disclose health information, 
unless it is needed to preserve the scientific integrity of the study. 
3. 
BACKGROUND INFORMATION AND RATIONALE 
3.1. 
Overview 
Focal segmental glomerulosclerosis (FSGS) is a pattern of histologic renal injury marked by 
segmental glomerular sclerosis and hyalinosis and may be either primary (idiopathic) or 
secondary. The renal injury results from insults directed at or within the podocyte that eventually 
lead to a rearrangement of the actin cytoskeleton and effacement of foot processes in the 
glomerular basement membrane. The histologic lesions differ in their location relative to the 
glomerular vascular and tubular poles and in the morphologic features of hyalinosis, capillary 
collapse, and hypercellularity (D’Agati et al, 2011).  
Primary, or idiopathic, FSGS is defined by the exclusion of another identifiable cause of FSGS. 
The glomerulosclerosis of secondary FSGS usually results from an adaptive response to scarring 
from a previous injury or direct toxic injury to the podocytes. Secondary FSGS may be associated 
with viral infections, be drug induced, or result from conditions marked by either reduced renal 
mass or elevated glomerular capillary pressures. It is important to distinguish primary from 
secondary FSGS as the latter is treated only with renin angiotensin system blockade and not 
immunosuppressive therapy. In addition to clinical history and laboratory findings such as 
hypoalbuminemia and hyperlipidemia, histological findings may help differentiate primary from 
secondary FSGS, with the former exhibiting more widespread foot process effacement under 
electron microscopy (D’Agati et al, 2011). 
Eighty percent of cases of FSGS are primary and the incidence of primary FSGS has dramatically 
increased over the past 20 to 30 years (D’Agati et al, 2011). Primary FSGS is usually a progressive 
disorder with a low likelihood of spontaneous remission. Approximately 50% of patients will reach 
end stage renal disease (ESRD) over a period of 5 to 8 years from the time of biopsy if either 
unresponsive to treatment or not treated (Korbet, 1999). Five to 10 percent of all pediatric and 
adult patients who progress to ESRD will have FSGS as their primary cause of renal failure 
(Malaga-Diequez et al, 2015). The prognosis of patients with primary FSGS is best predicted by 
the severity of proteinuria and the response to therapy. Patients who undergo a complete remission 
(CR) or partial remission (PR) have a much better chance of renal survival, 80% or greater over a 
10-year period, than those who are unresponsive (Troyanov et al, 2005). 
The goal of therapy is to induce CR of proteinuria that in turn leads to the preservation of renal 
function. The achievement of PR or even substantial reductions in proteinuria translates into less 
rapid loss of renal function. Adult patients with primary FSGS who have nephrotic range 
proteinuria are usually treated with renin angiotensin system blockade and immunosuppressive 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 35 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
therapy. Seventy percent of adults with primary FSGS will have nephrotic range proteinuria 
(Kitiyakara et al, 2003). The initial Kidney Disease Improving Global Outcomes (KDIGO) 
recommended immunosuppressive therapy for most adults with primary FSGS is oral prednisone, 
with calcineurin inhibitors (CNI) reserved for those at high risk for glucocorticoid-induced 
toxicity. There is no universal agreement on the dose and duration of prednisone therapy, though 
the current KDIGO Clinical Practice Guidelines for glomerulonephritis recommends treatment 
with high doses of prednisone, 1 mg/kg/day or 2 mg/kg every other day, for between 4 and 16 
weeks or until CR. If CR occurs, prednisone is then tapered slowly over a 6-month period. If the 
FSGS is steroid resistant, the KDIGO recommended second-line treatment is a CNI for 4 to 6 
months, although CNI are not FDA-approved for this indication. If PR or CR occurs, it is 
recommended that the CNI be slowly tapered over at least 12 months. A combination of 
mycophenolate mofetil (MMF) and high dose dexamethasone is the KDIGO recommended 
alternative for patients who do not tolerate or respond to the CNI, although MMF is also not FDA-
approved for this indication (KDIGO Work Group, 2012). 
About 50% of patients with primary FSGS will be resistant to therapy with corticosteroids 
(Bose and Cattran, 2014). The prolonged duration of high doses of prednisone is frequently 
associated with significant side effects including the development or worsening of diabetes, 
weight gain, fluid retention, osteoporosis, behavioral changes, and infection. Between 30% and 
40% of patients resistant to steroids will also be resistant to CNIs, and in those who respond, 
relapse is common (Cattran et al, 2007). CNIs are also associated with significant side effects, 
such as hypertension and glucose intolerance, and the long-term nephrotoxicity associated with 
their use may potentially abrogate the benefit from the reduction in proteinuria. These side effects 
make a number of patients with FSGS intolerant to the therapies. Thus a significant unmet need 
for efficacious therapies exists for both children and adults diagnosed with primary FSGS. 
As described in the Package Insert, H.P. Acthar® Gel (repository corticotropin injection, 
hereafter referred to as Acthar) is a highly purified porcine adrenocorticotropic hormone (ACTH) 
analogue (Mallinckrodt ARD LLC, 2015). Acthar is a purified sterile preparation of the ACTH 
formulated in 16% gelatin to provide a prolonged release after intramuscular or subcutaneous 
injection. ACTH is a member of the family of structurally related peptides known as melanocortin 
peptides. Melanocortin peptides, which in addition to ACTH include the α-, β-, and γ-melanocyte 
stimulating hormones, are derived from the natural protein pro-opiomelanocortin. They bind to 
cell surface G-protein coupled receptors known as melanocortin receptors (MCRs). Five subtypes 
of MCRs have been identified to date (MC1R-MC5R), each with different tissue distributions, 
binding affinity characteristics, and physiological roles (Getting, 2006). ACTH is a known agonist 
for all 5 subtypes of MCR (Schioth et al, 1995) and recent experiments demonstrate that Acthar 
also has agonist activity for all 5 MCRs (Wright, 2018). 
The kidney is a major target of the melanocortin hormone system. MCRs have been expressed 
throughout the kidney, including on glomerular podocytes, and receptor activations initiate 
downstream signaling cascades that ultimately lead to amelioration of renal injury (Gong and 
Dworkin, 2010). Agonists of the MC1R receptor were shown to reduce oxidative stress and 
improve glomerular morphology in nephrotic rats with passive Heymann nephritis (Lindskog et 
al, 2010). Acthar has been shown to diminish podocyte injury and apoptosis and reduce foot 
process effacement in a rodent subtotal nephrectomy model, an animal model of FSGS (Gong and 
Dworkin, 2010). In addition to improved podocyte structure and function, glomerulosclerosis, 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 36 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
tubule-interstitial nephritis, renal inflammation, tubular injury and tubular epithelial to 
mesenchymal transformation were all reduced in this model. 
Clinical studies on patients with primary FSGS have provided evidence for the therapeutic effect 
of ACTH (including Acthar) on proteinuria. In an observational study, 1 patient with FSGS and 
nephrotic range proteinuria who was resistant to steroid and cytotoxic therapy was treated with 
synthetic ACTH and attained PR (Berg and Arnadottir, 2004). A published case report 
documented the development of PR in a young woman with FSGS and massive proteinuria 
(greater than 10 grams) who was treated with Acthar (80 units [U] subcutaneously [SC] twice 
weekly for 6 months) after having failed to respond to corticosteroids, mycophenolate and a CNI 
(Bomback et al, 2011). In a prospective open label study, 3 patients with FSGS resistant to at least 
2 previous therapies were treated with Acthar 80 U SC twice a week for 6 months and 1 patient 
attained CR (Bomback et al, 2012).  
The largest experience of treating primary FSGS with Acthar is in 24 adult patients with nephrotic 
syndrome and FSGS where 16 patients were studied prospectively. Twenty-two patients had 
received prior immunosuppressive therapy, 21 of which had received at least one course of 
corticosteroids. Patients had received a mean of 2.2 ± 1.2 immunosuppressives prior to receiving 
Acthar. During treatment with Acthar, 19 patients received no other immunosuppressives. Data 
was available for 23 of 24 patients with 1 patient being lost to follow up after 5 weeks of Acthar. 
Seven of the 24 patients had remission of proteinuria, 5 with PR and 2 with CR and 5 of the 7 
patients had sustained remission with a median follow up time of 90 weeks (Hogan et al, 2013).  
3.2. 
Product Description 
Acthar is currently approved in the US for inducing a diuresis or remission of proteinuria in the 
nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus 
(Mallinckrodt ARD LLC, 2015). Acthar is a proprietary ACTH mixture isolated from porcine 
pituitary extracts.  
3.3. 
Dosage and Administration 
Investigational medicinal product (IMP) will be used to denote active drug (Acthar) and/or 
matching placebo. 
In this study all subjects will receive open label treatment with Acthar 1 mL (80 U) SC 3 times 
per week (3x/week) for 50 weeks. Taper to 1 mL SC twice a week (2x/week) for safety and/or 
tolerability reasons will be allowed. If the dose is tapered to 1 mL SC 2x/week it must remain at 
this level for the remainder of the study. Subjects unable to tolerate 1 mL SC 2x/week will be 
discontinued. 
3.4. 
Rationale 
The doses for this study were chosen based on safety and feasibility data. The prescribing 
information for Acthar recommends the use of 40 to 80 U administered intramuscularly or SC 
every 24 to 72 hours in adults and children over 2 years of age; the specific dose is 
individualized according to the medical condition (Mallinckrodt ARD LLC, 2015). The maximal 
dose is 80 to 120 U SC daily, which has been used safely for the treatment of acute multiple 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 37 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
sclerosis exacerbations over a period of 2 to 3 weeks. Recently published data suggests that 
based on serum cortisol-equivalent exposure (assuming linearity), 80 U of Acthar equates to 
30 mg of intravenous methylprednisolone (Lal et al, 2015).  
Higher doses of Acthar and longer periods of exposure are well tolerated and associated with 
improved outcomes in patients with idiopathic nephrotic syndrome. In the largest published 
experience of Acthar in FSGS, patients received treatment for 16 to 56 weeks and the side effect 
profile was considered acceptable (Hogan et al, 2013). A case report of 10 patients with 
treatment resistant FSGS documented that prolonged therapy with synthetic ACTH for a median 
of 18 months was well tolerated (Berg et al, 2012). In a study of patients with membranous 
nephropathy, another cause of idiopathic nephrotic syndrome, higher exposure to Acthar was 
well tolerated and associated with higher rates of remission of proteinuria (Hladunewich et al, 
2014). 
3.5. 
Risk/Benefit 
Known potential risks of Acthar include potential Cushing’s Syndrome, hypertension, 
gastrointestinal perforation and bleeding, behavioral and mood disturbances, hyperglycemia, 
enhanced risk for infection, decrease in bone density and/or worsening of peripheral edema 
(Mallinckrodt ARD LLC, 2015). 
Primary FSGS is a progressive disorder associated with a low likelihood of spontaneous 
remission and high risk of reaching ESRD if not treated or unresponsive to treatment. The 
incidence of primary FSGS is increasing, as is the number of patients reaching ESRD because of 
the disorder. Current therapies are inefficacious in a large number of patients and are associated 
with significant side effects that limit their use and potentially abrogate their benefit. Evidence 
suggests that Acthar will be beneficial in reducing proteinuria and the subsequent deterioration in 
renal function in patients who are resistant or intolerant to currently recommended treatments. 
4. 
OBJECTIVES 
4.1. 
Primary Objective 
 
Primary Objective 
Primary Endpoints 
To confirm the safety and tolerability of 
Acthar in the induction of remission of 
proteinuria in subjects with primary FSGS 
who are resistant to, or intolerant of, at 
least 1 prior immunosuppressive therapy 
 
Severity and frequency of adverse events (AEs) 
 
Changes in physical findings 
 
Changes in clinical laboratory findings 
 
Changes in vital signs 
 
 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 38 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
4.2. 
Secondary Objectives 
There are no secondary objectives or endpoints. 
4.3. 
Exploratory Objective(s) 
 
Primary Objective 
Primary Endpoints 
Exploratory Objectives 
Exploratory Endpoints 
 
To demonstrate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 39 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
5. 
STUDY DESIGN 
5.1. 
Description 
This is a multicenter, multiple dose study to examine the effect of Acthar in adult subjects with 
FSGS who have failed to achieve remission with, or who are intolerant of, one or more previous 
immunosuppressive therapies. Approximately 60 subjects will be enrolled. 
All enrolled subjects will be treated with Acthar 1 mL (80 U) SC 3x/week for 50 weeks. Taper to 
1 mL SC 2x/week for safety and/or tolerability reasons will be allowed. If the dose is tapered to 
1 mL SC 2x/week it must remain at this level for the remainder of the study. Subjects unable to 
tolerate 1 mL SC 2x/week will be discontinued.  
All subjects will participate in the Follow-up Period at the conclusion of their participation in the 
study (including those who terminate early). The Follow-up Period will be 4 to 6 weeks in 
duration, depending on the dose of Investigational Medicinal Product (IMP). 
For subjects receiving IMP 3x/week, the dose of IMP will be tapered to 2x/week for 2 weeks and 
then discontinued. For subjects receiving IMP 2x/week (tapered from 3x/week to 2x/week for 
safety), the IMP will be discontinued without a taper. All subjects, including those who terminate 
early, will then have an End of Study/Early Termination Visit 4 weeks after their last dose of 
IMP.  
5.2. 
Approximate Duration of Subject Participation 
Subjects will participate in the study for a total of approximately 65 weeks, including a 
Screening Visit/Visit 1 period of up to 9 weeks, and active treatment period of up to 50 weeks, 
and a follow-up visit of up to 6 weeks after discontinuation of IMP.  
5.3. 
Approximate Duration of Study 
The duration of the study from first subject first visit to last subject last visit will be dependent 
on the ability of the sites to identify and enroll eligible subjects. The entire study is expected to 
require approximately 5 years to complete.  
5.4. 
Approximate Number of Subjects 
Approximately 60 subjects will be enrolled at approximately 100 sites globally. 
6. 
SELECTION OF SUBJECTS 
6.1. 
Inclusion Criteria 
Subjects must meet all of the following criteria for inclusion in the study at the Screening 
Visit/Visit 1 and the Baseline Visit/Visit 2: 
1. Must be adequately informed and understand the nature and risks of the study and must 
be able to provide a signature and date on the ICF. 
2. Must be ≥ 18 years of age at Screening Visit/Visit 1 and can be male or female. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 40 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
3. Female subjects must be of nonchildbearing potential (history of hysterectomy, bilateral 
oophorectomy, or are postmenopausal with no history of menstrual flow in the 12 months 
prior to Screening Visit/Visit 1), or if of childbearing potential must be nonpregnant, 
nonlactating and agree to use effective contraception with a male partner throughout 
study participation and for 4 weeks after ending study participation. Acceptable forms of 
contraception include hormonal measures (oral contraceptive pills, contraceptive patch, 
contraceptive ring, injections), intrauterine devices, double barrier method (condom plus 
diaphragm, condom or diaphragm plus spermicidal gel or foam), and abstinence.  
4. Must have a history of primary FSGS confirmed by a renal biopsy. 
5. Must be willing to undergo a renal biopsy unless the most recent renal biopsy ≤ 3 years 
of the Screening Visit/Visit 1. 
6. Must have a total urine protein creatinine ratio (uPCR)  3.0 mg/mg at Screening 
Visit/Visit 1. 
7. Must have an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2 at the 
Screening Visit/Visit 1 as calculated by the 4-variable modification of diet in renal 
disease (MDRD) study equation. 
8. Must have failed to achieve sustained CR or PR of proteinuria as determined by the 
investigator with ≥ 1 prior immunosuppressive therapy, or must have intolerance to ≥ 1 
prior immunosuppressive therapy. 
9. Must have been treated with an angiotensin converting enzyme inhibitor (ACEi) or 
angiotensin receptor blocker (ARB) for ≥ 4 weeks prior to Screening Visit/Visit 1 and on 
stable maintenance dose(s) for ≥14 days prior to Screening Visit/Visit 1 and are expected 
to remain on that dose for the duration of the study or have a documented intolerance to 
ACEi or ARB with approval from the MM prior to enrollment. Subjects taking other 
antihypertensive medication(s), must be on a stable dose of for ≥ 4 weeks prior to the 
Screening Visit/Visit 1. 
10. Must have a mean systolic blood pressure ≤ 150 mm Hg and a diastolic blood pressure of 
≤ 90 mm Hg determined by the average of ≥ 3 seated readings taken at least 5 minutes 
apart at Screening Visit/Visit 1 and at the Baseline Visit/Visit 2. 
11. Must be able to communicate effectively with study personnel. 
12. Must be able and willing to follow all protocol requirements and study restrictions. 
13. Must be able and willing to return for all study visits. 
6.2. 
Exclusion Criteria 
Subjects are ineligible for study participation if they meet any of the following criteria at the 
Screening Visit/Visit 1 or Baseline Visit/Visit 2: 
1. Is from a vulnerable population, as defined by the US CFR Title 45, Part 46, Section 
46.111(b) and other local and national regulations, including but not limited to, 
employees (temporary, part-time, full time, etc) or a family member of the research staff 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 41 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
conducting the study, or of the sponsor, or of the clinical research organization, or of the 
IRB/IEC. 
2. Is unwilling to receive, or is intolerant of, subcutaneous injections. 
3. Has any history of use of ACTH preparations for treatment of nephrotic syndrome 
(including but not limited to Acthar and Synacthen®). 
4. Has a history of sensitivity to ACTH preparations (including but not limited to Acthar 
and Synacthen). 
5. Has a history of sensitivity to porcine protein products. 
6. Has a body mass index (BMI) 45 kg/m2 at Screening Visit/Visit 1. 
7. Has secondary FSGS, including but not limited to, obesity, known genetic cause, reduced 
kidney mass, Human Immunodeficiency Virus (HIV), intravenous heroin abuse, or sickle 
cell anemia (a full list of secondary causes of FSGS is included in Section 24.3). 
8. Cannot have failed to achieve sustained CR or PR of proteinuria, as determined by the 
investigator, on more than 2 prior immunosuppressive therapies with different 
mechanisms of action. 
9. Has had a renal biopsy demonstrating  50% global glomerular sclerosis, or  50% 
cortical interstitial fibrosis, or collapsing FSGS. 
10. Has any known contraindication(s) to Acthar (Mallinckrodt ARD LLC, 2015) including, 
but not limited to: 
 Any known history of scleroderma, osteoporosis, or ocular herpes simplex. 
 Any current uncontrolled hypertension, primary adrenocortical insufficiency, or 
adrenal cortical hyperfunction. 
 Any current congestive heart failure (defined as New York Heart Association 
Functional Class III to IV). 
 Peptic ulcer (within 6 months prior to Screening Visit/Visit 1). 
 Recent major surgery (within 6 months prior to Screening Visit/Visit 1, renal 
biopsy is not considered an exclusionary surgical procedure). 
11. Has a history of chronic active hepatitis; acute or chronic hepatitis B; or acute or chronic 
hepatitis C. 
12. Has a history of tuberculo/sis (TB) infection, any signs/symptoms of TB, or any close 
contact with an individual with an active TB infection. 
13. Has a clinically significant infection requiring intravenous administration of antibiotics 
and hospitalization in the 4 weeks prior to Screening Visit/Visit 1. 
14. Has known immune compromised status, including but not limited to, individuals who 
have undergone organ transplantation or who are known to be positive HIV. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 42 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
15. Has Type 1 or Type 2 diabetes mellitus (prior diagnosis of gestational diabetes mellitus is 
not exclusionary). 
16. Has had any of the following in the 12 weeks prior to Screening Visit 1/Visit 1: unstable 
angina confirmed by a cardiologist, myocardial infarction, coronary artery bypass graft, 
percutaneous trans-luminal coronary angioplasty, transient ischemic attack or 
cerebrovascular disease, unstable cardiac arrhythmia, or resuscitated sudden cardiac 
death. 
17. Has any solid tumor malignancy currently diagnosed or undergoing therapy, or has received 
therapy for any solid tumor malignancy in the 5 years prior to Screening Visit/Visit 1, with 
the exception of treated and cured basal cell carcinoma, treated and cured squamous cell 
carcinoma of the skin, and treated and cured carcinoma in situ of the cervix. 
18. Has a diagnosis of, is undergoing therapy for, or has received therapy for a hematologic 
malignancy in the 5 years prior to Screening Visit/Visit 1. 
19. Has been treated with any of the medications outlined in Table 2 within the specified 
timeframe prior to the Screening Visit/Visit 1. 
Table 2: Prohibited Medications Relative to Screening Visit/Visit 1 
24 weeks before 
Screening 
Visit/Visit 1 
12 weeks before 
Screening 
Visit/Visit 1 
8 weeks before Screening 
Visit/Visit 1 
4 weeks before Screening 
Visit/Visit 1 
Rituximab 
Investigational 
treatment for FSGS 
Intravenous/intramuscular 
corticosteroidsa, c 
Therapeutic drug/device trial 
(except FSGS) 
Cyclophosphamide 
Chronic oral 
corticosteroidsa,b 
 
 
aDoes NOT include corticosteroids (enteral or parenteral) used for the treatment of FSGS. 
bChronic use is defined as any dose of corticosteroid taken  4 consecutive weeks. 
cAny dose of parenteral corticosteroids 8 weeks prior to Screening Visit/Visit 1. 
 
20. Has been treated with any of the medications outlined in Table 3 within the specified 
timeframe prior to Baseline Visit/Visit 2. 
Table 3: 
Prohibited Medications Relative to Baseline Visit/Visit 2 
FSGS Treatment at Screening Visit/Visit 1a 
Days Prior to Baseline/Visit 2 
CNI 
 49 days 
Corticosteroidsb, Mycophenolate, Mofetil 
 30 days 
aIf subject is not currently receiving immunosuppressant treatment for FSGS at the Screening Visit/Visit 1, the 
Baseline Visit/Visit 2 will occur 2 days and  63 days after the Screening Visit/Visit 1. 
bCorticosteroids used for the treatment of FSGS (see exclusion Criterion 14 for corticosteroid use to treat other 
conditions). 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 43 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 
21. Has current or recent (within 6 months of the Screening Visit/Visit 1) drug or alcohol 
abuse as defined in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, 
Diagnostic Criteria for Drug and Alcohol Abuse (American Psychiatric Association, 
2013). 
22. Has any of the following laboratory abnormalities at the Screening Visit/Visit 1: 
 Hemoglobin ≤ 8.0 g/dL. 
 Platelets ≤ 50,000 cells/μL. 
 Absolute neutrophil count (ANC) ≤ 1,000 cells/μL. 
 Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total 
bilirubin  2 times the upper limit of normal (ULN). 
 Glycosylated hemoglobin (HbA1c)  6.5%. 
 Positive Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody 
(HBcAb). 
 Positive Hepatitis C virus antibody (HCV) and HCV polymerase chain reaction 
(PCR) ≥ 25 IU/mL (HCV PCR will be automatically analyzed if HCV is 
positive). 
 Positive or indeterminate interferon gamma release assay (IGRA). 
23. Has any other clinically significant disease, disorder or laboratory abnormality 
(including those listed on the Prescribing Information Section 5: Warnings and 
Precautions [Mallinckrodt ARD LLC, 2015]) which, in the opinion of the investigator (by 
its nature or by being inadequately controlled), might put the patient at risk due to 
participation in the study, or may influence the results of the study or the subject’s ability 
to complete the study. 
6.3. 
Screen Failure 
Subjects will be allowed to repeat any screening procedure once, as long as the results of the 
repeated procedure will be available within the screening visit window. This will not be 
considered a screen failure. The period from the start of the screening visit to the baseline visit 
must not exceed 63 days, inclusive of any repeated procedures. 
A subject who is a screen failure at the Screening Visit/Visit 1 or at the Baseline Visit/Visit 2 
may be rescreened once. During the rescreening period, subjects will be allowed to repeat any 
screening procedure once, as long as the results of the repeated procedure will be available 
within the screening visit window. The period from the start of the rescreening visit to the 
baseline visit must not exceed 63 days, inclusive of any repeated procedures. 
Subjects may only be rescreened once. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 44 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
7. 
PRIOR AND CONCOMITANT MEDICATION 
The start and stop date, dose, unit, frequency, route of administration, and indication for prior 
medications and concomitant medications taken within the past 30 days will be recorded.  
In addition, all prior treatments for FSGS will be recorded with start and stop date, dose, unit, 
frequency and route of administration. 
7.1. 
Prohibited Concomitant Medications 
The following treatments will not be permitted during the study: 
 Any long-acting corticotropin other than IMP. 
 Any enteral or parenteral corticosteroid use (topical, inhaled and intra-articular 
corticosteroids are allowed). 
 Administration of live or live-attenuated vaccines. 
 Enteral or parenteral immunosuppressive medications including, but not limited to 
methotrexate, azathioprine, cyclophosphamide, cyclosporine, tacrolimus, MMF, 
rituximab (or other B-cell inhibitors), and tumor necrosis factor inhibitors (eg, 
Enbrel®, Humira®, Remicade®); intraocular immunosuppressive medications are 
allowed. 
 Any investigational drug, device, or procedure administered as part of a research 
study.  
If any prohibited medication is taken during the study, all pertinent information will be recorded 
in source documents and the electronic case report form (eCRF). The designated study MM must 
be informed immediately so the sponsor may determine whether to continue the subject in the 
study. 
7.2. 
Permitted During Study 
If any medication is taken during the study, all pertinent information will be recorded in source 
documents and the eCRF.  
Subjects should remain on stable doses of ACEi and/or ARB during the study. An adjustment in 
the dose of these medications would represent a protocol deviation, but would not necessarily 
mandate study termination. Adjustments in dose of a concomitant medication should be 
documented in the subject’s source documents and eCRF. 
8. 
PROCEDURES 
The schedule of study procedures is summarized in the Schedule of Study Events (Table 1). 
8.1. 
Screening Visit/Visit 1 (Study Days -63 to -3) Procedures 
Screening assessments must be performed within 3 to 63 days prior to the Baseline Visit/Visit 2. 
The following procedures will be performed at the Screening Visit/Visit 1: 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 45 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 Informed consent. 
 Note: Subjects (US only) with stored renal biopsy samples will be reconsented after 
implementation of Amendment 3 to allow for sponsor contact and permission for 
additional sample examination. 
 Inclusion/exclusion criteria. 
 Contact the Interactive Phone/Web Response System (IXRS). 
 Medical and surgical history. 
 Current medical condition review. 
 Demographics. 
 Vital signs. 
 Height and Weight.  
 Complete physical examination. 
 Clinical laboratory tests. 
 
 
 HbA1c. 
 Serum pregnancy test.  
 Hepatitis serology.  
 IGRA test for TB (to be performed locally). 
 Urinalysis. 
 
 
 
 
NOTE: A separate consent is required for this procedure. 
 Dispense 24-hour urine collection materials. 
 Adverse events (AEs) and concomitant medications. 
Subjects who are taking immunosuppressant medication for FSGS at the time of the Screening 
Visit/Visit 1 must discontinue their use and complete a washout period of appropriate length 
before the Baseline Visit/Visit 2 (Table 4).  
Table 4: 
Timing of Baseline Visit/Visit 2 Relative to FSGS Treatment at Screening 
FSGS Treatment at Screening Visit/Visit 1 
Timing of Baseline Visit/Visit 2 
CNI 
 49 days and  63 days after drug discontinuation 
Corticosteroids, MMF 
 30 days and  63 days after drug discontinuation 
No treatment 
Eligibility is confirmed and IMP is on-site. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 46 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 
Subjects will be allowed to repeat any screening procedure, if necessary, if it is within the 
screening time window. A screening procedure can be repeated only once; if the repeat 
procedure continues to be exclusionary, the subject will be a screen failure. 
8.2. 
Baseline Visit/Visit 2 Procedures 
The timing of the Baseline Visit/Visit 2 will depend on the washout period for the 
immunosuppressives the subject is taking at screening. The subject will collect a 24-hour urine 
3 days prior (± 2 days) to Baseline Visit/Visit 2. 
The investigator or designee will complete the following procedures at the Baseline Visit/Visit 2:  
 Inclusion/exclusion criteria review; subject must meet all eligibility criteria at 
Screening Visit/Visit 1 and Baseline Visit/Visit 2. 
 Current medical condition review. 
 Limited physical examination. 
 Vital signs. 
 Weight (height from Visit 1 will be used to calculate BMI at Visit 2). 
 Clinical laboratory tests.  
 Nonfasting lipid panel. 
 
 
 Urine pregnancy test. 
 Urinalysis. 
 
 
 
 
 
 
 
 
 
. 
 Subject diary training. 
 Contact IXRS and dispense IMP kits. 
 IMP administration under supervision of study staff and observation for at least 1 
hour thereafter.  
 AEs and concomitant medications. 
8.3. 
Visit 3 Procedures (Week 4 ± 5 Days) 
 Current medical condition review. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 47 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 Limited physical examination. 
 Vital signs. 
 Weight. 
 Clinical laboratory tests. 
 Urine pregnancy test. 
 
 
 IMP accountability. 
 Study diary review. 
 Contact IXRS and dispense IMP kits. 
 AEs and concomitant medications. 
8.4. 
Visit 4 Procedures (Week 8 ± 5 Days) 
 Current medical condition review. 
 Limited physical examination. 
 Vital signs. 
 Weight. 
 Clinical laboratory tests. 
 
 
 Urine pregnancy test. 
 Urinalysis. 
 
 
 
 
 IMP accountability. 
 Study diary review. 
 Contact IXRS and dispense IMP kits. 
 AEs and concomitant medications. 
8.5. 
Visit 5 Procedures (Week 12 ± 5 Days) 
 Current medical condition review. 
 Limited physical examination. 
 Vital signs. 
 Weight. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 48 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 Clinical laboratory tests. 
 Nonfasting lipid panel. 
 HbA1c. 
 Urine pregnancy test. 
 
 
 IMP accountability. 
 Study diary review. 
 Contact IXRS, dispense IMP kits. 
 AEs and concomitant medications. 
8.6. 
Visit 6 Procedures (Week 16 ± 5 Days) 
 Current medical condition review. 
 Limited physical examination. 
 Vital signs. 
 Weight. 
 Clinical laboratory tests. 
 
 
 Urine pregnancy test. 
 Urinalysis. 
 
. 
 
 
 IMP accountability. 
 Study diary review. 
 Contact IXRS and dispense IMP kits. 
 AEs and concomitant medications. 
8.7. 
Visit 7 Procedures (Week 20 ± 5 Days) 
 Current medical condition review. 
 Limited physical examination. 
 Vital signs. 
 Weight. 
 Clinical laboratory tests. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 49 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 Urine pregnancy test. 
 
 
 IMP accountability. 
 Study diary review. 
 Contact IXRS and dispense IMP kits. 
 Dispense 24-hour urine collection materials. 
 AEs and concomitant medications. 
8.8. 
Visit 8 Procedures (Week 24 ± 5 Days) 
 Current medical condition review. 
 Limited physical examination. 
 Vital signs. 
 Weight. 
 Clinical laboratory tests. 
 Nonfasting lipid panel. 
 HbA1c. 
 
 
 Urine pregnancy test. 
 Urinalysis. 
 
 
 
 
 
 
 IMP accountability. 
 
 
 
 
 Study diary retraining. 
 Study diary review. 
 Contact IXRS and dispense IMP kits. 
 AEs and concomitant medications. 
8.9. 
Visit 9 Procedures (Week 26 + 5 Days) 
 Current medical condition review. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 50 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 Limited physical examination. 
 Vital signs. 
 Weight. 
 Urine pregnancy test. 
 
 
 IMP accountability. 
 Study diary review. 
 Contact IXRS and dispense IMP kits. 
 AEs and concomitant medications. 
8.10. 
Visit 10 Procedures (Week 30 ± 5 Days)  
 Current medical condition review. 
 Limited physical examination. 
 Vital signs. 
 Weight. 
 Clinical laboratory tests. 
 Urine pregnancy test. 
 
 
 IMP accountability. 
 Study diary review. 
 Contact IXRS and dispense IMP kits. 
 AEs and concomitant medications. 
8.11. 
Visit 11 Procedures (Week 34 ± 5 Days) 
 Current medical condition review. 
 Limited physical examination. 
 Vital signs. 
 Weight. 
 Clinical laboratory tests. 
 
 
 Urine pregnancy test. 
 Urinalysis. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 51 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 
 
 
 
 IMP accountability. 
 Study diary review. 
 Contact IXRS and dispense IMP kits. 
 AEs and concomitant medications. 
8.12. 
Visit 12 Procedures (Week 38 ± 5 Days)  
 Current medical condition review. 
 Limited physical examination. 
 Vital signs. 
 Weight. 
 Clinical laboratory tests. 
 Nonfasting lipid panel. 
 HbA1c. 
 Urine pregnancy test. 
 
 
 IMP accountability. 
 Study diary review. 
 Contact IXRS and dispense IMP kits. 
 AEs and concomitant medications. 
8.13. 
Visit 13 Procedures (Week 42 ± 5 Days)  
 Current medical condition review. 
 Limited physical examination.  
 Vital signs. 
 Weight. 
 Clinical laboratory tests. 
 
. 
 Urine pregnancy test. 
 Urinalysis. 
 
 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 52 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 
 
 IMP accountability. 
 Study diary review. 
 Contact IXRS and dispense IMP kits. 
 AEs and concomitant medications. 
8.14. 
Visit 14 Procedures (Week 46 ± 5 Days)  
 Current medical condition review. 
 Limited physical examination. 
 Vital signs.  
 Weight. 
 Clinical laboratory tests. 
 Urine pregnancy test. 
 
 
 IMP accountability. 
 Study diary review. 
 Contact IXRS and dispense IMP kits. 
 Dispense 24-hour urine collection materials. 
 AEs and concomitant medications. 
8.15. 
Visit 15 Procedures (Week 50 ± 5 Days) 
 Current medical condition review. 
 Limited physical examination. 
 Vital signs. 
 Weight. 
 Clinical laboratory tests. 
 Nonfasting lipid panel. 
 HbA1c. 
 
 
 Urine pregnancy test. 
 Urinalysis. 
 
 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 53 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 
 
 
 
 
 
 
 
 Study diary review. 
 IMP accountability. 
 Contact IXRS.  
 AEs and concomitant medications. 
8.16. 
End of Study/Early Termination Visit Procedures 
All subjects will have an End of Study/Early Termination Visit 4 weeks after their last dose of 
IMP. 
Subjects receiving IMP 3x/week, will have IMP tapered to 2x/week for 2 weeks at Week 50 and 
then discontinued. These subjects will return at Week 56 + 5 days for their End of Study Visit. 
Subjects receiving IMP 2x/week will discontinue dosing without a taper. These subjects will 
return at Week 54 + 5 days for their End of Study Visit. 
Subjects who discontinue study participation at any other time in the study will have their dose 
tapered to 1 mL SC 2x/week (if required) and return for the Early Termination Visit 4 weeks 
after their last dose of IMP. 
The following assessment will be done at the End of Study/Early Termination Visit 
 Current medical condition review. 
 Complete physical examination. 
 Vital signs, including weight. 
 Clinical laboratory tests. 
 Urine pregnancy test. 
 Urinalysis 
 IMP accountability (subjects who required taper only). 
 Study diary review. 
 Contact IXRS. 
 AEs and concomitant medications. 
8.17. 
Taper Safety Visit 
 Current medical condition review. 
 Limited physical examination. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 54 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 Vital signs. 
 Weight. 
 Clinical laboratory tests (if the reason for discontinuation was related to laboratory 
test results). 
 IMP accountability. 
 Study diary review. 
 AEs and concomitant medications. 
9. 
INVESTIGATIONAL MEDICINAL PRODUCT 
9.1. 
Methods of Assigning Subjects to Treatment Groups 
The investigator or designee will contact IXRS to register subjects at Visit 1. The subject’s 
identification (ID) number will be determined by the IXRS and will be used to identify the 
subjects for the duration of the study within all systems and documentation. Subject ID numbers 
will consist of 7 digits: the first 4 digits reflect the site number assigned to the Investigator and 
the last 3 digits are the subject number. 
A subject ID number will not be assigned to more than 1 subject. If a subject is not eligible to 
receive treatment, or should a subject discontinue from the study, the subject ID number cannot 
be reassigned to another subject. 
In the event that a subject is rescreened within the screening window, they do not need a new 
subject ID number. At the Baseline Visit/ Visit 2, qualified subjects who meet all of the 
eligibility criteria will be enrolled into the study. The investigator or designee must contact IXRS 
to record each subject visit and receive the IMP kit assignments. 
The investigator or designee must contact the IXRS to report subjects as a screen failure if the 
enrolled subject does not meet eligibility criteria at the Baseline Visit/Visit 2. 
The investigator or designee must contact the IXRS to report all subject visits and status changes. 
The investigator must maintain a subject master log linking the subject ID to the subject’s name. 
The investigator must follow all applicable privacy laws in order to protect a subject’s privacy 
and confidentiality. Information that could identify a subject will be masked on material received 
by the sponsor. 
9.2. 
Emergency Identification of Investigational Medicinal Product 
This is an unblinded study. 
9.3. 
Dosing Procedures 
The following Acthar treatments are to be administered. The study treatment schedule is as noted 
in Table 5. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 55 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
Table 5: 
IMP Treatment Schedule 
Study Week 
Study Period 
Study Drug 
Dose 
Weeks 0 to 50 
Open Label/Open-label 
Extension  
Acthar 
1 mL SC 3x/weeka 
Weeks 50 to 51b 
Follow-up Period (taper) 
Acthar 
1 mL SC 2x/week 
aDose can be tapered to 1 mL SC 2x/week for safety and/or tolerability reasons. If a subject ends study participation prior to 
Week 50, the dose of Acthar should be tapered to 1 mL SC 2x/week for 2 weeks. 
bSubjects receiving Acthar 1 mL (80 U) SC 3x/week should be tapered to 1 mL SC 2x/week for 2 weeks, with a final visit 4 
weeks after the last dose of Acthar. Subjects in the open-label extension receiving 1 mL SC 2x/week at Week 49 will stop 
dosing at the conclusion of Week 49, with a final Visit 4 weeks after the last dose of Acthar. 
 
The subject or subject’s caregiver will administer the first dose of IMP in the clinic under the 
supervision of study staff. The subject will remain in the clinic for at least 1 hour post dose to 
monitor for allergic or anaphylactic reaction(s). After Visit 2, all doses will be administered by 
the subject or the subject’s caregiver at home. 
Throughout the trial, IMP cannot be taken on 2 consecutive days and cannot be taken more than 
3 days apart, regardless of dosing frequency. 
9.3.1. 
Dose Reduction 
The dosing of Acthar should be tapered from 3x/week to 2x/week for safety reasons if a subject 
meets any of the following criteria: 
 Development of accelerated hypertension (defined as systolic blood pressure ≥ 180 
and diastolic blood pressure ≥ 100 mm Hg) that cannot be managed with adjustment 
of concomitant medications such as antihypertensive medications. 
 Development of an edema score of 4 at any visit that cannot be managed with 
adjustment of concomitant medications such as diuretics (see Section 24.2). 
 Development of congestive heart failure that cannot be managed with adjustment of 
concomitant medications such as diuretics and antihypertensive medications. 
 Development of diabetic signs/symptoms (ie, HbA1c  8%, or fasting plasma glucose 
 126 mg/dL, or classic symptoms of hyperglycemia with random plasma glucose 
 200 mg/dL). 
 Development of any other AE of at least moderate intensity that cannot be managed 
with adjustment of concomitant medications. 
Any subject whose dose is tapered for any of the reasons described above will have a Taper 
Safety Visit scheduled 2 weeks after the start of the taper. 
9.3.2. 
Treatment Discontinuation 
Treatment with Acthar should be discontinued for safety purposes if the reduction in dosing to 
2x/week and adjustment of concomitant medications does not manage the following: 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 56 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 Persistent accelerated hypertension (defined as systolic blood pressure ≥ 180 and 
diastolic blood pressure ≥ 100 mm Hg). 
 Persistent edema score of 4 (see Section 24.2). 
 Persistent congestive heart failure.  
 Persistent diabetic signs/symptoms (ie, HbA1c  8%, or fasting plasma glucose 
 126 mg/dL, or classic symptoms of hyperglycemia with random plasma glucose 
 200 mg/dL). 
 Any other AE of at least moderate intensity that cannot be managed with adjustment 
of concomitant medications. 
The investigator should discontinue subjects for safety purposes any time during the study if the 
subject meets any of the following criteria: 
 Development of unexplained and sustained (2 consecutive visits) worsening of 
disease defined as unresolved progression or 30% decline in eGFR from baseline, or 
if the subjects remains at significant risk of sequelae of nephrotic syndrome (such as 
serum albumin  2.8 mg/dL) and sustained worsening of uPCR ( increase  50% 
from baseline). 
 Development of ESRD and requirement for chronic renal replacement therapy. 
 Administration of live or live-attenuated vaccines after Screening Visit/Visit 1. 
 Diagnosis of a malignancy or lymphoproliferative disorder. 
 Pregnancy during the course of the study. 
 Development of an independent disease that requires treatment with 
immunosuppressive therapy or plasma exchange therapy. 
 Development of a contraindication to IMP use. 
 Use of any investigational drug, device, or procedure as part of a research study. 
9.4. 
Description of IMP 
Acthar is a highly purified sterile preparation of prolonged-release porcine ACTH analogue in 
16% gelatin for intramuscular or SC injection. Acthar contains 0.5% phenol, not more than 0.1% 
cysteine (added), sodium hydroxide and/or acetic acid to adjust pH, and water for injection. 
Acthar is obtained from processing porcine pituitary using a FDA approved process. 
Acthar is supplied as 5 mL multidose vials. Acthar vials contain 80 U of ACTH per mL. The 
vials should not be over pressurized prior to withdrawing the product. The vials should be 
warmed to room temperature before using and will be labeled according to all applicable national 
and local regulations. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 57 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
9.5. 
Storage of Clinical Supplies 
IMP will be maintained in a temperature controlled, secure locked area with restricted access at 
the study site.  
IMP will be supplied in kits containing the appropriate amount of vials according to the 
treatment group to which the subject is assigned. IMP will be stored under refrigeration between 
2° to 8°C (36° to 46°F). Please refer to the Pharmacy Manual for complete information regarding 
storage and accountability of IMP. 
9.6. 
Drug Accountability 
In accordance with ICH requirements, the investigator will, at all times, be able to account for all 
IMP furnished to the study site. A drug accountability record will be maintained for this purpose. 
The investigator must maintain accurate records indicating dates and quantity of IMP received, 
to whom it was dispensed (subject-by-subject accounting) and accounts of any IMP accidentally 
or deliberately destroyed. All unused IMP not involved in immediate subject dosing will be 
maintained under locked, temperature-controlled storage at the study site.  
9.7. 
Compliance Monitoring 
Prior to beginning the administration of IMP, subjects and/or their caregiver will be trained on 
dosing administration and must exhibit proper technique. Subjects and/or their caregiver will be 
trained on the completion of the study diary and will complete a study diary entries to record all 
IMP administration and will bring it, along with all IMP kits including used vials to each visit. 
Each time IMP is dispensed compliance will be encouraged. Subject diary training is an ongoing 
process as the diary will be reviewed with the subject at each visit to monitor compliance with 
IMP administration. 
10. 
SAFETY ASSESSMENTS AND PROCEDURES 
The following safety assessments will be evaluated: AEs, physical examinations, clinical 
laboratory test results (chemistry, hematology, HbA1c, 
, and urinalysis, 
 
hepatitis serology, IGRA for TB test) and vital signs. All safety assessments will be performed at 
times outlined in the Schedule of Study Events (Table 1). Additional (unscheduled) safety 
assessments may be performed as needed. 
10.1. 
Adverse Events 
AEs will be collected from signing of the ICF and followed by the investigator until the AE is 
resolved or stabilized. AEs occurring prior to the administration of IMP will only be reported if 
they are related to study procedures. Any and all safety measures (which includes standard of 
care activities) should be provided by the study site to the subject. Any study site follow-up 
should be documented. 
Refer to Section 13.4 for additional details on the handling of AEs and SAEs. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 58 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
10.2. 
Medical and Surgical History  
Medical and surgical history will be obtained at the Screening Visit/Visit 1. Medical history will 
include a review of the following systems: general, dermatological, respiratory, cardiovascular, 
gastrointestinal, genitourinary, gynecological, endocrine, musculoskeletal, hematological, 
neuropsychological, immune (allergies), and head, eyes, ears, nose, and throat. Historical and 
current medical conditions including date of last menstrual period for female subjects will be 
recorded.  
10.3. 
Current Medical Conditions 
At each visit after screening, subjects will be asked about any changes in medical conditions, 
specifically new medical conditions and worsening of existing medical conditions. Any changes 
since the Screening Visit/Visit 1 will be recorded as AEs, as appropriate. 
10.4. 
Physical Examinations 
A complete physical examination will be performed at the Screening Visit/Visit 1 and the End of 
Study/Early Termination Visit. The complete physical examination includes evaluation of the 
head, eyes, ears, nose, throat, neck (including thyroid), cardiovascular system (including 
assessment of heart, peripheral pulses, presence or absence of edema), lungs, abdomen 
(including liver and spleen, bowel sounds), lymph nodes, musculoskeletal system (including 
spine, joints, muscles) neurological system (including cranial nerves, reflexes, sensation, 
strength), skin, extremities and other conditions of note. 
A limited physical examination, including evaluation of lungs, heart, abdomen, extremities and 
assessment for edema will be done at all other visits.  
The findings of the physical examinations will be recorded. Any change from the Screening 
Visit/Visit 1 physical examination that is considered clinically significant by the investigator will 
be recorded as an AE.  
10.5. 
Vital Signs 
Vital signs will be obtained after the subject has been seated for 5 minutes (minimum) and will 
include systolic and diastolic blood pressures, pulse rate, respiratory rate, and body temperature. 
Additionally, at the Screening Visit/Visit 1 and the Baseline Visit/Visit 2, blood pressure will be 
measured at least 3 times, with 5 minutes between assessments after the subject has been seated 
for a minimum of 5 minutes prior to the initial blood pressure assessment. 
The investigator may perform additional unscheduled vital sign measurements to evaluate or 
manage a suspected AE. These unscheduled vital sign measurements should be obtained after the 
subject has been seated for at least 5 minutes, if possible. Unscheduled vital signs will be 
recorded. 
At a minimum, the date of vital signs at the Screening Visit/Visit 1 will be recorded. The date 
and time for all other vital signs will be recorded. 
Screening/Baseline  

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 59 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
A subject with systolic blood pressure  150 mm Hg and diastolic blood pressure  90 mm Hg 
(average of 3 assessments) at the Screening Visit/Visit 1 or Baseline Visit/Visit 2 does not 
qualify for the study. 
On Study Assessments 
If an on-study vital sign is not in the reference range, an AE will be recorded if the investigator 
determines the change is clinically significant or requires a change in the subject’s clinical 
management.  
10.6. 
Height and Weight 
Height will be collected at screening only. Weight will be collected at specified times during the 
study. 
10.7. 
Clinical Laboratory Tests, HbA1c, Serum Cystatin C, Serum 
Electrolytes,IGRA, Urinalysis, and Pregnancy Tests 
The clinical laboratory tests are listed in Section 24.1. All clinical laboratory tests will be done at 
a central laboratory facility except urine pregnancy (at the site) and IGRA (local laboratory). 
Specific instructions for collection, storage and shipment of clinical laboratory samples will be 
provided in a separate laboratory manual. 
Samples for laboratory testing at all visits may be collected under fasted or nonfasted conditions. 
The date and time of the sample collection must be documented on the laboratory report. 
Investigators must review and sign laboratory reports. The clinical significance of each 
laboratory abnormality will be documented. New clinically significant laboratory abnormalities 
or clinically significant changes in laboratory values will be reported as AEs, as appropriate. 
Hematology with differential, serum chemistry, other specific tests, and urinalysis samples will 
be collected at the specific times starting at screening and throughout the study. 
In addition: 
 All female subjects of child-bearing potential will have a serum pregnancy test at the 
Screening Visit/Visit 1, and a urine pregnancy test at the Baseline Visit/Visit 2 and at 
specified visits throughout the study. Results must be available prior to dosing with 
protocol mandated IMP. Subjects with positive results will be ineligible for study 
entry (Screening Visit/Visit 1) or withdrawn from the study. Any female subject that 
becomes pregnant during the study will be immediately withdrawn and the pregnancy 
report as per Section 13.5. 
If applicable, the subject’s agreement to use contraception throughout their study 
participation, and for 4 weeks after ending study participation, will be documented. 
 HBsAg and HBcAb will be performed at the Screening Visit/Visit 1. Results of these 
tests must be negative or nonreactive for subjects to qualify for the study.  
 HCV will be performed at the Screening Visit/Visit 1. A positive HCV will 
automatically trigger a HCV PCR analysis. HCV PCR must be  25 IU/mL to qualify 
for the study. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 60 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 IGRA for TB will be performed at the Screening Visit/Visit 1. Results of this test 
must be negative for subjects to qualify for the study.  
 HbA1c. 
 Non-fasting lipid panel including total cholesterol, high density lipoprotein (HDL), 
low density lipoprotein (LDL), and triglycerides. 
 
 
Out-of-range Laboratory Values 
Laboratory values from samples collected at the Screening Visit/Visit 1 will be evaluated by the 
investigator for eligibility of the subject in the study. 
Laboratory values that fall outside the reference range from samples collected during the study or 
at study exit or early termination will be assessed by the investigator for clinical significance. If 
the out of range value for samples is deemed clinically significant by the investigator, an AE will 
be recorded. 
11. 
EXPLORATORY ASSESSMENTS 
The following exploratory assessments will be evaluated at times specified in the Schedule of 
Study Events (Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 61 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
12. 
STATISTICAL METHODS AND PLANNED ANALYSIS 
12.1. 
General Considerations 
Data will be listed, analyzed, and included in the clinical study report. Data will be analyzed as 
described in the statistical analysis plan. Descriptive statistics for continuous variables will 
include number of values, mean, SD, median, minimum, and maximum, unless otherwise noted. 
Frequency and percentages will be calculated for categorical variables. All statistical significance 
testing will be 2-tailed using α = 0.05, unless otherwise specified. Data summary and analyses 
will be performed with SAS 9.2 or higher. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 62 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
12.2. 
Analysis Populations 
 The Intent to Treat (ITT) Population will include all enrolled subjects who receive 1 or 
more doses of IMP and who contribute any exploratory data to the study.  
 The Per Protocol Population will include the subset of the ITT population who 
complete the study as per protocol. Completer populations will be further defined in 
the statistical analysis plan. 
 The Safety Population will include all enrolled subjects who receive 1 or more doses of 
IMP. 
12.3. 
Efficacy Assessments 
12.3.1. 
Primary Efficacy Endpoint 
There is no primary efficacy endpoint. 
12.3.2. 
Secondary Efficacy Endpoints 
There are no secondary efficacy endpoints. 
12.4. 
Primary Safety Endpoints 
The primary safety endpoints to be evaluated include a summary of the general safety profile 
including AEs (serious and non-serious), physical examinations, clinical laboratory tests, vital 
signs, medical and surgical history, height and height.  
12.5. 
Exploratory Endpoints 
Exploratory endpoints will examine 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 63 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
 
  
  
 
Exploratory endpoints include: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
12.6. 
Subject Characteristics 
12.6.1. 
Demographics 
All dosed subjects enrolled in the study will be included in a listing of subject demographic 
characteristics. Summary statistics tables will present the data for all dosed subjects combined as 
well as for completers only. 
12.6.2. 
Medical and Surgical History 
The medical and surgical history data will not be summarized but will be presented in a data 
listing. 
12.6.3. 
Concomitant Medications 
Concomitant medications will not be summarized but will be presented in a data listing. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 64 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
12.6.4. 
Subject Disposition and Exposure to IMP 
The number of subjects who complete the study and who do not complete the study, both overall 
and according to reasons for discontinuation from the study, will be summarized for all dosed 
subjects. Subject disposition will be presented in a data listing. 
12.7. 
Safety Analysis 
All subjects who receive at least 1 dose of IMP will be included in the safety analyses. 
12.7.1. 
Adverse Events 
AEs will be coded using MedDRA. All AEs will be presented in a data listing. Only treatment-
emergent adverse events (TEAEs) will be included in all summaries. 
TEAEs, treatment related TEAEs, severity of TEAEs, and TEAEs leading to early 
discontinuation will be summarized by system organ class and preferred term for all dosed 
subjects at the treatment level and overall. All TEAEs leading to early discontinuation will be 
presented in data listings. 
12.7.2. 
Clinical Laboratory Tests 
Clinical laboratory testing will be presented in data listings. 
12.7.3. 
Physical Examination Findings 
All physical examination results will be presented in a data listing. 
12.7.4. 
Vital Signs/Height and Weight 
Vital sign measurements (diastolic blood pressure, systolic blood pressure, respiratory rate, pulse 
rate, body temperature, weight and height) will be presented in a data listing. 
12.8. 
Interim Analysis 
Not applicable. 
12.9. 
Statistical Power and Sample Size Consideration 
Formal sample size calculations were not performed. 
12.10. 
Deviations From Statistical Analysis Plan 
Any deviations from the planned statistical analysis will be described and justified in the final 
clinical study report as appropriate. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 65 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
13. 
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 
13.1. 
Safety 
For safety information about Acthar refer to the most recent version of the Prescribing 
Information (Mallinckrodt ARD LLC, 2015). 
13.2. 
Definitions 
Adverse Event 
An AE is any untoward or undesirable medical occurrence in a subject who is administered an 
IMP, which does not necessarily have to have a causal relationship with this treatment. Examples 
of AEs include but are not limited to: 
 Clinically significant laboratory findings. 
 Clinically significant changes in physical examination findings. 
 An AE occurring due to IMP overdose whether accidental or intentional. 
 An AE occurring from IMP abuse. 
 An AE associated with IMP withdrawal. 
 Unexpected AE. 
An unexpected AE is defined as an AE, the nature and severity of which is not consistent with 
the applicable product information in the most recent version of the Investigator’s Brochure. 
Serious Adverse Event 
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose 
results in any of the following outcomes: 
 Death. 
 A life-threatening AE. 
 Inpatient hospitalization or prolongation of existing hospitalization. 
 A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions. 
 Results in a congenital anomaly/birth defect. 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, may 
jeopardize the subject or subject and may require medical or surgical intervention to prevent one 
of the outcomes listed above. Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency department or at home, blood dyscrasias or 
convulsions that do not result in inpatient hospitalization, or the development of drug 
dependency or drug abuse. 
Death 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 66 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
Death is an outcome of an event. The event that resulted in death should be recorded and 
reported on the SAE Form. All causes of death must be reported as SAEs. The investigator 
should make every effort to obtain and send death certificates and autopsy reports to 
Mallinckrodt. 
Life-threatening Event 
A life-threatening event refers to immediate risk of death as the event occurred per the reporter. 
A life-threatening event does not include an event that, had it occurred in a more severe form, 
might have caused death but, as it actually occurred, did not create an immediate risk of death. 
For example, hepatitis that resolved without evidence of hepatic failure would not be considered 
life-threatening, even though hepatitis of a more severe nature can be fatal. Similarly, an allergic 
reaction resulting in angioedema of the face would not be life-threatening, even though 
angioedema of the larynx, allergic bronchospasm, or anaphylaxis can be fatal. 
Hospitalization 
Hospitalization is defined as an official admission to a hospital. Hospitalization or prolongation 
of a hospitalization constitutes a criterion for an AE to be serious; however, it is not in itself 
considered an SAE. In absence of an AE, a hospitalization or prolongation of a hospitalization 
should not be reported by the investigator as an SAE. Such situations include, but are not limited 
to, the following: 
 A hospitalization or prolongation of hospitalization is needed for a procedure required 
by the protocol. 
 A hospitalization or prolongation of hospitalization is part of a routine procedure 
followed by the center (eg, stent removal after surgery). This should be recorded in 
the study file. 
 A hospitalization for a preexisting condition that has not worsened. 
Note that a visit to the emergency department or other hospital department of less than 24 hours 
that does not result in admission (unless considered "important medical event" or life-threatening 
event) is not considered an SAE in Mallinckrodt clinical studies. 
13.3. 
Adverse Event and Serious Adverse Event Classifications 
IMP Relatedness 
The following classifications should be used when evaluating the relationship of AEs or SAEs to 
study treatment (Table 7). 
Table 7: 
Adverse Event Relationships 
Relationship 
Definition 
Not Related 
No relationship between the experience and the administration of study treatment; related 
to other etiologies such as concomitant medications or subject’s clinical state. 
Unlikely Related 
The current state of knowledge indicates that a relationship is unlikely. 
Possibly Related 
A reaction that follows a plausible temporal sequence from administration of the study 
treatment and follows a known response pattern to the suspected study treatment. The 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 67 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
Relationship 
Definition 
reaction might have been produced by the subject’s clinical state or other modes of 
therapy administered to the subject. 
Related 
A reaction that follows a plausible temporal sequence from administration of the study 
treatment and follows a known response pattern to the suspected study treatment and can 
be confirmed with a positive re-challenge test or supporting laboratory data. 
 
Severity Assessment 
For purposes of consistency, if required the investigator may use the intensity grades presented 
in Table 8. 
Table 8: 
Adverse Event Severity Grades 
Grade 
Definition 
Mild 
Does not interfere with subject's usual function and activities 
Moderate 
Interferes to some extent with subject's usual function and activities 
Severe 
Interferes significantly with subject's usual function and activities 
 
If an AE increases in severity (eg, from moderate to severe); decreases in severity (eg, changes 
from moderate to mild); or there is a change in seriousness, a new AE will be opened and the 
original AE will be closed. If an AE is still ongoing at the time of a subject’s completion of the 
follow-up visit, the resolution/stop date and time is left blank. 
To ensure there is no confusion or misunderstanding of the difference between the terms 
“serious” and “severe,” which are not synonymous, the following note of clarification is 
provided: 
The term “severe” is used to describe the intensity (severity) of a specific event (as in mild, 
moderate, or severe myocardial infarction); the event itself, however, may be of relatively minor 
medical importance (such as a severe headache). This is not the same as “serious,” which is 
based on the subject/event outcome or action criteria usually associated with events that pose a 
threat to a subject's life or functioning. Seriousness (not severity) serves as a guide for defining 
regulatory reporting obligations. 
13.4. 
Adverse Event and Serious Adverse Event Recording and Reporting 
AEs and SAEs will be collected from signing of the ICF through completion of the end of 
study/early termination visit. All AEs and SAEs should be recorded in source documents; all 
AEs and SAEs that occur following the first dose of IMP should also be recorded in the eCRF. 
The investigator is required to record the AE or SAE regardless of the severity of the event or its 
relationship to study treatment. Prior to the first dose at the Baseline Visit/Visit 2, only AEs and 
SAEs related to study procedures will be recorded on the eCRF. The investigator must follow up 
on all AEs and SAEs reported to have occurred 30 days after study completion until the event 
has resolved or stabilized or at such time the investigator refers the subject to a nonstudy 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 68 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
physician. The investigator will document the further follow-up information in the subject’s 
source document.  
During the period specified above, the investigator will: 
 Record all AEs and SAEs from the signing of the ICF through the completion of the 
End of Study/Early Termination visit 
 Report all SAEs on an SAE Report Form to Global Pharmacovigilance. 
 Report all pregnancies to Global Pharmacovigilance on the Pregnancy Surveillance 
Form. 
 Submit any Expedited Safety Report or Suspected Unexpected Serious Adverse 
Reaction from Global Pharmacovigilance to the IRB/IEC. 
The reporting requirements for AEs are summarized in Table 9. 
Table 9: 
Reporting Requirements for Adverse Events 
Seriousness 
Reporting Time 
Type of Report 
All Serious 
Within 24 hours of first knowledge 
of event 
Initial report on the SAE Form, appropriate 
eCRF, and source document 
Within 24 hours of receipt of follow-
up information 
Follow up report on the SAE Form, 
appropriate eCRF, and source document 
Nonserious 
Per case report form submission 
procedure 
Appropriate eCRF and source document 
 
Adverse Events 
AEs can be reported spontaneously or elicited during open-ended questioning (ie, "How have 
you been feeling since your last visit?"), examination, or evaluation of a subject. Signs and 
symptoms must be recorded using standard medical terminology. For subjects incapable of 
giving consent, the legally acceptable representative may provide information regarding the 
subject’s status. 
All fields on the AE CRF page should be completed for each event with a full description of the 
event and date of onset/start and resolution/stop. A medical diagnosis if known, should be 
recorded in lieu of each individual sign and symptom associated with the diagnosis and 
experienced by the subject. If no medical diagnosis is known, the term used by the subject to 
describe the event or signs noted by the site personnel should be recorded.  
Serious Adverse Events 
Initial Reporting 
SAEs (based on FDA/ICH definition of an SAE) require immediate reporting to Global 
Pharmacovigilance.  

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3 
  Page 69 of 79 
CONFIDENTIAL AND PROPRIETARY 

For all SAEs, the investigator, or designee, must complete the SAE Report Form with 
the minimum information required by FDA and ICH and fax it to Mallinckrodt at +1 
314-654-5759 or email at pvclinical@mnk.com within 24 hours of first knowledge of 
the event even if the experience does not appear to be related to the IMP.

The investigator, or designee, will receive acknowledgement of receipt of the SAE
report form from Mallinckrodt.

Should the investigator or designee have any difficulty in sending the SAE report,
they may contact Mallinckrodt based on the information in the Study Operations
Manual.

If there is any doubt about whether the information constitutes an SAE, the
information is to be treated as an SAE.
The investigator(s) or designee is required to submit the any expedited safety report or suspected 
unexpected serious adverse reaction to the responsible IRB/IEC. 
The sponsor will ensure that any expedited safety report or suspected unexpected serious adverse 
reaction are submitted to the FDA and other regulatory agencies as appropriate. 
Follow Up Reporting 
The investigator or designee must complete an SAE report form for all follow-up information 
received and fax it to Mallinckrodt at +1 314-654-5759 within 24 hours of receipt. 
The investigator(s) or designee will receive acknowledgement of receipt for each SAE report 
form from Mallinckrodt. 

The investigator or designee is required to provide all related information/supporting
documentation of an SAE until the SAE is resolved or stabilized or the subject has
been referred to a nonstudy physician for follow-up treatment.

The investigator(s) or designee is required to submit the safety alert to the responsible
IRB/IEC.

The sponsor will ensure that any expedited safety report or suspected unexpected
serious adverse reaction are submitted to the FDA and other regulatory agencies as
appropriate.
13.5. 
Pregnancy Reporting 
Certain information, although not considered an SAE, must be recorded, reported, and followed 
up as indicated. This includes the following:  
Pregnancy exposure to an investigational medicinal product, except for exposure to prenatal 
vitamins. Subjects should not become pregnant during the study. If the subject becomes 
pregnant, study treatment must be discontinued immediately. The investigator must report the 
pregnancy by submitting the appropriate form to Global Pharmacovigilance (fax at +1 314-654- 
5759 or email at pvclinical@mnk.com within 24 hours of confirmation of a pregnancy (ie, 
positive serum pregnancy test result). The outcome of pregnancy (eg, spontaneous abortion, live 
birth, still birth, congenital anomalies, birth defects) must be reported by submitting the 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3 
  Page 70 of 79 
CONFIDENTIAL AND PROPRIETARY 
appropriate form to Global Pharmacovigilance (fax at +1 314-654-5759 or email at 
pvclinical@mnk.com within 24 hours of the pregnancy outcome being submitted to the study 
site. If the pregnancy results in a live birth, a postdelivery follow-up will be performed at least 28 
days after the baby is born and must be reported to Global Pharmacovigilance (fax at +1 
314-654-5759 or email at pvclinical@mnk.com) within 24 hours of the study site becoming 
aware of the follow-up information. Both maternal and paternal investigational medicinal 
product exposures are collected.  
If the female partner of a male subject becomes pregnant during the study, the site will forward 
the Pregnancy Notification form and the Pregnancy Report Fax cover page to Global 
Pharmacovigilance (fax at +1 314-654-5759 or email at pvclinical@mnk.com), within 24 hours 
of being notified. The outcome of pregnancy (eg, spontaneous abortion, live birth, still birth, 
congenital anomalies, birth defects) must be reported by submitting the appropriate form to 
Global Pharmacovigilance (fax at +1 314-654-5759 or email at pvclinical@mnk.com) within 
24 hours of the pregnancy outcome being submitted to the study site. If the pregnancy results in 
a live birth, a postdelivery follow-up will be performed at least 28 days after the baby is born 
and must be reported to Mallinckrodt Pharmacovigilance (fax at +1 314-654-5759 or email at 
pvclinical@mnk.com) within 24 hours of the study site becoming aware of the follow-up 
information. 
14.
SUBJECT DISCONTINUATION OR WITHDRAWAL
14.1. 
Subject Withdrawal 
Subjects who discontinue, or are withdrawn from the study for any reason, will be required to 
enter the follow-up period and have the end of study/early termination safety assessments 
(see Section 8.16) to assess their continued well-being.  
The reason for discontinuation will be recorded. A subject may be discontinued from the study 
for the following medical or administrative reasons: 
Withdrawal by Subject 
Subjects will be free to discontinue from the study at any time. Subjects who have received at 
least 1 dose of IMP but do not complete the study will not be replaced. 
Adverse Event 
If a dosed subject suffers an AE that, in the judgment of the investigator, sponsor or MM, 
presents an unacceptable consequence or risk to the subject, the subject will be discontinued 
from further participation in the study. 
Death 
In the event that a subject dies during the study, death will be the reason for discontinuation. 
Lost to Follow-up 
Every effort should be used to maintain contact with subjects during their participation in the 
study. A subject may be considered lost to follow-up if the there is no response to 3 attempts to 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3 
  Page 71 of 79 
CONFIDENTIAL AND PROPRIETARY 
reach the subject by telephone and no response to a certified letter sent to the last known address 
of the subject. Efforts to contact the subject should be noted in source documentation. 
Met Withdrawal Criteria 
If a subject develops a condition that meets any of the exclusion criteria (Section 6.2) or fails to 
meet an inclusion criteria (Section 6.1) during the study that is not considered to be an AE or is 
noncompliant (eg, has a positive pregnancy or drug screening test), the subject will be 
discontinued from further participation in the study. Discontinuation is also mandated for safety 
and/or tolerability issues as outlined in Section 9.3.2). 
Other 
If the above reasons are not applicable, please use the “Other” option and provide the appropriate 
reason for subject withdrawal. 
For subjects who discontinue or are withdrawn from the study for any reason, the investigator 
will notify the sponsor and when possible, the subject will be required to have the early 
termination safety assessments (Section 8.16) to assess their continued well-being. 
15.
STUDY SUSPENSION, TERMINATION, AND COMPLETION
The sponsor may suspend or terminate the study or part of the study at any time for any reason. 
If the investigator suspends or terminates the study, the investigator will promptly inform the 
sponsor and the IRB/IEC and provide them with a detailed written explanation. Upon study 
completion, the investigator will provide the sponsor, IRB/IEC, and regulatory agency with final 
reports and summaries as required by regulations. Study termination and follow-up will be 
performed in compliance with Mallinckrodt standard operating procedures.  
16.
PROTOCOL AMENDMENTS
Any change in the study plan requires a protocol amendment. An investigator must not make any 
changes to the study without IRB/IEC and sponsor approval except when necessary to eliminate 
apparent immediate hazards to the subjects. A protocol change intended to eliminate an apparent 
immediate hazard to subjects may be implemented immediately, but the change must then be 
documented in an amendment, reported to the IRB/IEC within 5 working days, and submitted to 
the appropriate regulatory agency in the required time frame.  
17.
QUALITY CONTROL AND ASSURANCE
The sponsor performs quality control and assurance checks on all clinical studies that it sponsors. 
Before enrolling any subjects in this study, sponsor personnel and the investigator review the 
protocol, the IB, the eCRFs and instructions for their completion, the procedure for obtaining 
informed consent, and the procedure for reporting AEs and SAEs. A qualified representative of 
the sponsor will monitor the conduct of the study. During these study site visits, information 
recorded in the eCRFs will be verified against source documents. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 72 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
17.1. 
Study and Study Site Discontinuation Criteria 
The sponsor, investigator, or local and national regulatory authorities may discover conditions 
during the study that indicate that the study or study site should be terminated. This action may 
be taken after appropriate consultation between the sponsor and investigator. Conditions that 
may warrant termination of the study/study site include, but are not limited to: 
 The discovery of an unexpected, serious, or unacceptable risk to the subjects enrolled 
in the study. 
 The decision on the part of the sponsor to suspend or discontinue testing, evaluation 
or development of the IMP. 
 Failure of the investigator to enroll subjects into the study at an acceptable rate. 
 Failure of the investigator to comply with pertinent regulations. 
 Submission of knowingly false information from the study site to the sponsor, study 
monitor, or local and national regulatory authorities. 
 Insufficient adherence to protocol requirements. 
 Study/study site termination and follow-up will be performed in compliance with 
Mallinckrodt standard operating procedures. 
18. 
DIRECT ACCESS, DATA HANDLING, AND RECORD-KEEPING 
18.1. 
Investigator 
The investigator will permit study-related monitoring, audits, IRB/IEC review, and regulatory 
inspections by providing direct access to original source data and documents. 
All subject information will be recorded on source documents. The eCRFs must be fully 
completed and include all required data for all subjects enrolled. All eCRF data must be 
submitted to the sponsor throughout and at the end of the study. 
If an investigator retires, relocates, or otherwise withdraws from conducting the study, the 
investigator must notify the sponsor to agree upon an acceptable storage solution. Regulatory 
agencies will be notified with the appropriate documentation. 
Any significant changes in study personnel will require an updated Statement of Investigator (ie, 
FDA form 1572) to be filed with the sponsor. 
The investigator must notify their IRB/IEC of protocol deviations in accordance with local 
regulatory and IRB/IEC requirements. 
18.2. 
Sponsor 
The eCRF data are stored in a database and processed electronically. The sponsor’s medical 
monitor reviews the data for safety information. The data are reviewed for completeness, and 
logical consistency. Automated validation programs will identify missing data, out-of-range data, 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 73 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
and other data inconsistencies. Clinical laboratory data will be processed electronically. Requests 
for data clarification are forwarded to the study site for resolution. 
19. 
SUBJECT INJURY 
In general, subject to specific provisions in the clinical trial agreement, if a subject is injured as a 
direct result of an investigational medicinal product, the sponsor will pay for reasonable and 
necessary medical treatment for the injury, to the extent that such expenses are not covered by 
the subject’s medical insurance, a government program, or other responsible third party. If laws 
or regulations of the locality in which the study is taking place require additional payment of 
expenses, the sponsor shall comply with such laws or regulations. Where applicable, the sponsor 
has taken specific national insurance. 
20. 
RECORDS RETENTION 
The investigator shall retain and preserve 1 copy of all data collected or databases generated in 
the course of the study, specifically including but not limited to those defined by GCP as 
essential. Essential documents should be retained until at least 2 years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of 
clinical development of the investigational medicinal product. These documents should be 
retained for a longer period, however, if required by the applicable regulatory requirements or by 
an agreement with the sponsor. It is the responsibility of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained. Prior to 
destruction of any study essential documents, the investigator must first obtain written approval 
from the sponsor. 
21. 
BIOLOGICAL SAMPLES 
Blood and tissue samples will be used only for scientific research. Each sample will be labeled 
with a code so that the laboratory personnel testing the samples will not know the subject’s 
identity. After the study ends, the clinical laboratory samples will be destroyed, with the 
exception of urine and serum samples for 
 
 
 The subject 
may request that his or her samples, if still identifiable, be destroyed at any time; however, any 
data already collected from that sample will still be used for this research. 
22. 
PUBLICATION POLICY 
22.1. 
Sponsor’s Publication Policy 
The sponsor’s policy is to publish or otherwise communicate the results of its hypothesis-testing 
clinical studies, regardless of outcome, for marketed products, compound(s) or product(s) being 
investigated that are later approved for marketing. Hypothesis-testing clinical studies are those 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 74 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
studies intended to provide meaningful results by examining prestated questions using 
predefined statistically valid plans for data analysis, thereby providing firm evidence of safety 
and/or efficacy to support product claims. 
Exploratory studies, in contrast, serve to set direction for possible future studies. They have 
significant statistical limitations, provide only preliminary information about a disease, 
condition, or product, and are not designed to provide final conclusions on product claims. The 
sponsor does not commit to publish or otherwise communicate the results of every exploratory 
study, because this information is of an exploratory nature and often highly proprietary. 
However, if information from an exploratory study is of significant medical importance, the 
sponsor will publish or otherwise communicate the results. 
The sponsor’s decision to publish or otherwise publicly communicate the results of this study 
will be made in accordance with all applicable laws, regulations, and sponsor policies regarding 
publication and communication of clinical study results. 
22.2. 
Investigator’s Ability to Publish 
Terms and provisions of publication rights are governed by the publication section in the clinical 
trial agreement. 
23. 
REFERENCES 
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 
(5th Edition). 2013. Washington, DC. 
Barisoni L, Schnaper HW, Kopp JB. A Proposed Taxonomy for the Podocytopathies: A 
Reassessment of the Primary Nephrotic Diseases. Clin. J. Am. Soc. Nephrol. 2007, 2, 529-542. 
Berg AL, Arnadottir M.  ACTH-induced improvement in the nephrotic syndrome in patients 
with a variety of diagnoses. Nephrol. Dial. Transplant. 2004, 19, 1305–1307. 
Berg AL, Dolinina, Bakoush O. Treatment of focal segmental glomerulosclerosis with ACTH. J. 
Am. So.c Nephrol. 2012, 23, 941A. 
Bomback AS, Tumlin JA, Baranski J, Bourdeau JE, Besarab A, et al. Treatment of nephrotic 
syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des. Devel. Ther. 2011, 5, 147–
153. 
Bomback AS, Canetta PA, Beck LH Jr, Ayalon R, Radhakrishnan J, et al. Treatment of resistant 
glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am. J. Nephrol. 
2012, 36, 58–67. 
Bose B, Cattran D. Toronto Glomerulonephritis Registry. Glomerular Diseases: FSGS. Clin. J. 
Am. Soc. Nephrol. 2014, 9, 626-632. 
Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, et al. Cyclosporin in idiopathic 
glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney 
Int. 2007, 72, 1429-47. 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 75 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
D’Agati VD, Kaskel FJ, Falk RJ. Focal Segmental Glomerulosclerosis. N. Engl. J. Med. 2011, 
365, 2398-2411.  
Getting SJ. Targeting melanocortin receptors as potential novel therapeutics. Pharmacol. Ther. 
2006, 111, 1-15. 
Gong R, Dworkin LD. ACTH (Acthar gel) prevents proteinuria and renal injury in the remnant 
kidney: evidence for direct podocyte protection. J. Am. Soc. Nephrol. 2010, 21, 548A. 
Hladunewich MA, Cattran D, Beck LH, Odutayo A, Sethi S, et al. A pilot study to determine the 
dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic 
syndrome due to idiopathic membranous nephropathy. Nephrol. Dial. Transplant. 2014, 29, 
1570-1577. 
Hogan J, Bomback AS, Mehta K, Canetta PA, Rao MK, et al. Treatment of idiopathic FSGS 
with adrenocorticotropic hormone gel. Clin. J. Am. Soc. Nephrol. 2013, 8, 2072-2081. 
Kidney Disease Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: 
KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int. 2012, Suppl 2, 139-274. 
Kitiyakara C, Kopp JB, Eggers P. Trends in the epidemiology of focal segmental 
Glomerulosclerosis. Semin. Nephrol. 2003, 23, 172-182. 
Korbet SM. Clinical picture and outcome of primary focal segmental glomerulosclerosis. 
Nephrol. Dial. Transplant. 1999, 14, 68-73. 
Lal R, Bell S, Challenger R, Hammock V, Nyberg M, et al. Pharmacodynamics and tolerability 
of repository corticotropin injection in healthy human subjects: a comparison with intravenous 
methylprednisolone. J. Clin. Pharmacol. 2015, Open Access Online publication 10 September 
2015. 
Lindskog A, Eberfors K, Johansson ME, Stefansson B, Granqvist A, et al. Melanocortin 1 
receptor agonists reduce proteinuria. J. Am. Soc. Nephrol. 2010, 21, 1290-1298. 
Malaga-Diequez L, Bouhassira D, Bipson D, Trachtman H. Novel therapies for FSGS: 
preclinical and clinical studies. Adv. Chronic Kidney Dis. 2015, 22, e1-e6. 
Wright D. Summary Report: In Vitro Binding Affinity (IC50) and Agonist Effects (EC50) of 
Acthar for Melanocortin Receptors.  Mallinckrodt ARD LLC, Bedminster NJ. 2018. 
Mallinckrodt ARD LLC. H.P. Acthar® Gel; Package Insert: Hazelwood, MO, 2015. 
Schiöth HB, Muceniece R, Wikberg JE, Chhajlani V. Characterization of melanocortin receptor 
subtypes by radioligand binding analysis. Eur. J. Pharmacol. 1995, 15, 311-317. 
Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Toronto Glomerulonephritis Registry 
Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. 
J. Am. Soc. Nephrol. 2005, 16, 1061-1608. 
 
 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 76 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
24. 
ATTACHMENTS 
24.1. 
Attachment 1: Clinical Laboratory Tests  
 
Serum Chemistry 
Alanine aminotransferase (ALT) 
Creatinine 
Albumin (total) 
Cystatin C 
Alkaline phosphatase  
Glucose 
Aspartate aminotransferase (AST) 
Hemoglobin A1c  
Bilirubin (total) 
Phosphorus 
Blood urea nitrogen 
Potassium 
Calcium 
Protein, total 
CO2 
Sodium 
Chloride 
Uric acid 
 
 
Lipid Panel 
Total cholesterol 
LDL 
HDL 
Triglycerides 
 
 
Hormones 
Serum and urine beta-human chorionic gonadotropin (pregnancy test) 
 
Hematology Assays 
Hematocrit 
Platelet count 
Hemoglobin 
Red blood cell count 
White blood cell count, including differential 
Absolute neutrophil count 
 
Urinalysis 
Blood 
Nitrite 
Clarity 
Nitrite 
Color 
Protein 
Glucose 
pH 
Leukocyte esterase 
Specific gravity 
Ketones 
 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 77 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
Serum Chemistry 
 
 
 
 
 
 
Hepatitis Serology 
Hepatitis B core antibody 
Hepatitis C virus antibody (HCV) 
Hepatitis B surface antigen 
Hepatitis C virus PCR (only if HCV +) 
TB Assay 
Interferon gamma release assay (IGRA) (obtained at local lab) 
 
 
 
24.2. 
Attachment 2: Evaluation of Edema 
The presence of edema will be assessed using the following guidelines. Firm pressure should be 
applied by thumb for 5 to 10 seconds over a bony area. 
Evaluation of Edema 
Score* 
0 
1 
2 
3 
4 
Depth of pit 
None 
0-2mm 
2-4 mm 
4-6 mm 
6-8 mm 
Description of 
pit 
none 
slight pitting 
somewhat deep 
pit 
pit is noticeably 
deep 
pit is very deep 
Time to pit 
disappearance 
none 
disappears 
rapidly
10-15 
seconds
1-2 minutes 
> 2 minutes 
Visible 
distortion 
none 
none 
none readily 
detectable 
dependent 
extremity 
appears fuller 
and swollen 
dependent 
extremity is 
grossly distorted 
*Assessment Chart for Pitting Edema adapted from the Guelph General Hospital Congestive Heart Failure Pathway. 
 
Edema should also be categorized as 1 or more of the following types: 
Categorization of Edema 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 78 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
Type 
Presacral 
Anasarca 
Brawny 
Localization 
pelvis 
general 
skin 
Edema 
evaluated as above 
generalized 
accompanied by 
fibrotic skin changes that 
may not pit
  
 
24.3. 
Attachment 3: Secondary Causes of FSGS 
 
1. Familial 
a. Mutations in 
 
b. Mutations in 
 
c. Mutations in 
 
d. Mutations in 
 
e. Mutations in 
 
f. Mutations in 
 
g. Mutations in 
 
h. Mutations in 
 
i. 
 
2. Virus associated 
 
a. HIV-associated nephropathy 
b. Parvovirus B19 
3. Medication 
 
a. Heroin-nephropathy 
b. Interferon-a 
c. Lithium 
d. Pamidronate/alendronate 
e. Anabolic steroids 
4. Adaptive structural-functional responses likely 
mediated by 
 
4.1 Reduced kidney mass 
a. Oligomeganephronia 
b. Unilateral kidney agenesis 
c. Kidney dysplasia 
d. Cortical necrosis 
e. Reflux nephropathy 
f. Surgical kidney ablation 
g. Chronic allograft nephropathy 
h. Any advanced kidney disease with reduction in 
functioning nephrons 
4.2 Initially normal kidney mass 
a. Diabetes mellitus 
b. Hypertension 
c. Obesity 

Mallinckrodt ARC LLC 
MNK1422 
Protocol MNK14224049 Amendment 3                                                                             Page 79 of 79 
 
CONFIDENTIAL AND PROPRIETARY 
 
1. Familial 
a. Mutations in 
 
b. Mutations in 
 
c. Mutations in 
 
d. Mutations in 
 
e. Mutations in 
 
f. Mutations in 
 
g. Mutations in 
 
h. Mutations in 
 
i. 
 
d. Cyanotic congenital heart disease 
e. Sickle cell anemia 
5. Malignancy 
 
 
6. Nonspecific pattern of FSGS caused by kidney 
scarring in glomerular disease 
a. Focal proliferative glomerulonephritis 
(IgA nephropathy, lupus nephritis, pauci-immune focal 
necrotizing and crescentic glomerulonephropathy) 
b. Hereditary nephritis (Alport syndrome) 
c. Membranous glomerulopathy 
d. Thrombotic microangiopathy 
Source: Adapted from Barsoni et al, 2007.